

10/ 088,814

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 4 APR 04 STN AnaVist \$500 visualization usage credit offered  
NEWS 5 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records  
NEWS 6 MAY 11 KOREAPAT updates resume  
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced  
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and  
USPATFULL/USPAT2  
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/CAPLUS  
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in  
INPADOC  
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and  
and display fields  
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL  
NEWS 13 JUL 11 CHEMSAFE reloaded and enhanced  
NEWS 14 JUL 14 FSTA enhanced with Japanese patents  
NEWS 15 JUL 19 Coverage of Research Disclosure reinstated in DWPI  
NEWS 16 AUG 09 INSPEC enhanced with 1898-1968 archive  
NEWS 17 AUG 28 ADISCTI Reloaded and Enhanced  
NEWS 18 AUG 30 CA(SM)/CAPLUS(SM) Austrian patent law changes  
  
NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:12:43 ON 30 AUG 2006

=> file reg

10/ 088,814

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:12:59 ON 30 AUG 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 29 AUG 2006 HIGHEST RN 905300-98-3  
DICTIONARY FILE UPDATES: 29 AUG 2006 HIGHEST RN 905300-98-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006


Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10088814.str



chain nodes :

11 18 19 20

ring nodes :

1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17

chain bonds :

7-11 11-12 18-19 19-20

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15  
15-16 16-17

exact/norm bonds :

7-11 11-12 18-19 19-20

normalized bonds :

1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15  
15-16 16-17

isolated ring systems :

containing 1 : 12 :

10/ 088,814

Hydrogen count :

9:= exact 1

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS  
20:CLASS 21:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sample

SAMPLE SEARCH INITIATED 10:13:19 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1354 TO ITERATE

100.0% PROCESSED 1354 ITERATIONS

36 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 24873 TO 29287

PROJECTED ANSWERS: 360 TO 1080

L2 36 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 10:13:26 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 28006 TO ITERATE

100.0% PROCESSED 28006 ITERATIONS

702 ANSWERS

SEARCH TIME: 00.00.01

L3 702 SEA SSS FUL L1

10/ 088,814

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'HCAPLUS' ENTERED AT 10:13:32 ON 30 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Aug 2006 VOL 145 ISS 10

FILE LAST UPDATED: 29 Aug 2006 (20060829/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 19 L3

=> d his

(FILE 'HOME' ENTERED AT 10:12:43 ON 30 AUG 2006)

FILE 'REGISTRY' ENTERED AT 10:12:59 ON 30 AUG 2006

L1 STRUCTURE UPLOADED

L2 36 S L1 SAMPLE

L3 702 S L1 FUL


FILE 'HCAPLUS' ENTERED AT 10:13:32 ON 30 AUG 2006

L4 19 S L3

=> d l4 1- ibib abs hitstr


YOU HAVE REQUESTED DATA FROM 19 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2006:331187 HCAPLUS  
 DOCUMENT NUMBER: 144:387654  
 TITLE: Aurora B is required for mitotic chromatin-induced phosphorylation of Opl8/Stathmin  
 AUTHOR(S): Gadea, Bedrick B.; Ruderman, Joan V.  
 CORPORATE SOURCE: Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA  
 SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2006), 103(12), 4493-4498  
 CODEN: PNASAG; ISSN: 0027-8424  
 PUBLISHER: National Academy of Sciences  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Oncoprotein 18/Stathmin (Opl8) is a microtubule-destabilizing protein that is inhibited by phosphorylation in response to many types of signals. During mitosis, phosphorylation of Opl8 by cdc2 is necessary but not sufficient for Opl8 inhibition. The presence of mitotic chromosomes is addnl. required and involves phosphorylation of Ser-16 in Xenopus Opl8 (and/or Ser-63 in human). Given that Ser-16 is an excellent Aurora A (Aur-A) kinase consensus phosphorylation site and the Aurora kinase inhibitor ZM447439 (ZM) blocks phosphorylation in the activation loop of Aur-A, we asked whether either Aur-A or Aurora B (Aur-B) might regulate Opl8. We find that ZM blocks the ability of mitotic chromatin to induce Opl8 hyperphosphorylation in Xenopus egg exts. Depletion of Aur-B, but not Aur-A, blocks hyperphosphorylation of Opl8, and chromatin assembled in the absence of Aur-B fails to induce hyperphosphorylation. These results suggest that Aur-B, which concs. at centromeres of metaphase chromosomes, contributes to localized regulation of Opl8 during the process of spindle assembly.  
 IT 331771-20-1, ZM447439  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Aurora B is required for mitotic chromatin-induced phosphorylation of Opl8/Stathmin)  
 RN 331771-20-1 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 2 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2006:87918 HCAPLUS  
 DOCUMENT NUMBER: 144:324127  
 TITLE: SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors  
 AUTHOR(S): Heron, Nicola M.; Anderson, Malcolm; Blowers, David P.; Breed, Jason; Eden, Jonathan M.; Green, Stephen; Hill, George B.; Johnson, Trevor; Jung, Frederic H.; McKen, Helen H. J.; Mortlock, Andrew A.; Pannifer, Andrew D.; Paupit, Richard A.; Pink, Jennifer; Roberts, Nicola J.; Rowse, Sian  
 CORPORATE SOURCE: AstraZeneca, Mereside, Cheshire, Macclesfield, SK10 4TG, UK  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(5), 1320-1323  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB A novel series of 5-aminopyrimidinyl quinazolines has been developed from anilino-quinazoline 1, which was identified in a high throughput screen for Aurora A. Introduction of the pyrimidine ring and optimization of the substituents both on this ring and at the C7 position of the quinazoline led to the discovery of compds. that are highly specific Aurora kinase inhibitors. Co-crystallization of one of these inhibitors with a fragment of Aurora A shows the importance of the benzamido group in achieving selectivity.  
 IT 331770-21-9 331771-20-1  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors)  
 RN 331770-21-9 HCAPLUS  
 CN Benzamide, N-[4-[[6,7-dimethoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331771-20-1 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 2 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1235291 HCAPLUS

DOCUMENT NUMBER: 144:82987

TITLE:

Prevention of MKK6-Dependent Activation by Binding to p38 $\alpha$  MAP Kinase

AUTHOR(S): Sullivan, Jane E.; Holdgate, Geoffrey A.; Campbell, Douglas; Timms, David; Gerhardt, Stefan; Breed, Jason; Breeze, Alexander L.; Birmingham, Alun; Pauptit, Richard A.; Norman, Richard A.; Embrey, Kevin J.; Read, Jon; VanScyoc, Wendy S.; Ward, Walter H. J. Molecular Enzymology, Respiratory and Inflammation Research, Computational Chemistry and Structural Biology, AstraZeneca, Macclesfield, Cheshire, SK10 4TG, UK

CORPORATE SOURCE: Biochemistry (2005), 44(50), 16475-16490

CODEN: BICHAW; ISSN: 0006-2960

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Inhibition of p38 $\alpha$  MAP kinase is a potential approach for the treatment of inflammatory disorders. MKK6-dependent phosphorylation of the activation loop of p38 $\alpha$  increases its catalytic activity and affinity for ATP. An inhibitor, BIRB796, binds at a site used by the purine moiety of ATP and extends into a "selectivity pocket", which is not used by ATP. It displaces the Asp168-Phe169-Gly170 motif at the start of the activation loop, promoting a "DFG-out" conformation. Some other inhibitors bind only in the purine site, with p38 $\alpha$  remaining in a "DFG-in" conformation. We now demonstrate that selectivity pocket compds. prevent MKK6-dependent activation of p38 $\alpha$  in addition to inhibiting catalysis by activated p38 $\alpha$ . Inhibitors using only the purine site do not prevent MKK6-dependent activation. We present kinetic analyses of seven inhibitors, whose crystal structures as complexes with p38 $\alpha$  have been determined. This work includes four new crystal structures and a novel assay to measure K<sub>d</sub> for nonactivated p38 $\alpha$ . Selectivity pocket compds. associate with p38 $\alpha$  over 30-fold more slowly than purine site compds., apparently due to low abundance of the DFG-out conformation. At concns. that inhibit cellular production of an inflammatory cytokine, TNF $\alpha$ , selectivity pocket compds. decrease levels of phosphorylated p38 $\alpha$  and p. Stabilization of a DFG-out conformation appears to interfere with recognition of p38 $\alpha$  as a substrate by MKK6. ATP competes less effectively for prevention of activation than for inhibition of catalysis. By binding to a different conformation of the enzyme, compds. that prevent activation offer an alternative approach to modulation of p38 $\alpha$ .

IT 872372-36-60, p38 $\alpha$  MAP kinase complex  
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(MPAQ, as p38 $\alpha$  MAP kinase inhibitor; compds. that bind to selectivity pocket of p38 $\alpha$  MAP kinase prevent its activation by MKK6 and inhibit catalysis by activated p38 $\alpha$ )

RN 872372-36-6 HCAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:614536 HCAPLUS

DOCUMENT NUMBER: 143:115392

TITLE:

Preparation of conjugated small molecules for diagnostic and therapeutic use

INVENTOR(S): Grottfeld, Robert M.; Milanov, Zdravko V.; Patel, Hitesh K.; Lai, Andiliy G.; Mehta, Shamal A.; Lockhart, David J.

PATENT ASSIGNEE(S): Ambit Biosciences Corp., USA

SOURCE: U.S. Pat. Appl. Publ., 63 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005153371	A1	20050714	US 2005-31638	20050107
WO 2005067644	A2	20050728	WO 2005-US456	20050107
WO 2005067644	A3	20051013		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG


PRIORITY APPLN. INFO.: US 2004-535173P P 20040107  
 US 2004-557941P P 20040330

GI



AB Provided herein are linker compds. and conjugates that include the linker compds. In one embodiment, the linker compds. comprise 2 or 3 residues of 6-aminohexanoic acid and optionally 7-10 residues of polyethyleneglycol

L4 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT:

64

THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

(PEG). The linker compds. are useful in forming conjugates with one or more components useful in biopharmaceutical or bioanal. applications. In particular, the biopharmaceutically useful compds. are kinase inhibitors. The conjugates described herein have utility in a variety of diagnostic, sepn., and therapeutic applications. Thus, I was prepd. from SB 202190, PEG-acide and the biotin-linker compd.

IT 857892-01-4P


RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of conjugated biotins for diagnostic and therapeutic use)

RN 857892-01-4 HCAPLUS


CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-N-[42-[4-[[[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]amino]carboxyl]phenyl]-6,13-dioxo-17,20,23,26,29,32,35,38-octaaza-7,14,41-triazadotetracont-1-yl]-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

PAGE 2-B



PAGE 3-A



ACCESSION NUMBER: 2005:470256 HCAPLUS

DOCUMENT NUMBER: 143:20052

TITLE: Urea derivatives as kinase modulators

INVENTOR(S): Milanov, Zdravko V.; Patel, Hitesh K.; Grotzfeld, Robert M.; Mehta, Shamal A.; Andiliy, Lai G.; Lockhart, David J.

PATENT ASSIGNEE(S): Ambit Biosciences Corporation, USA

SOURCE: PCT Int. Appl., 350 pp.

CODEN: PIXX02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005048948	A2	20050602	WO 2004-US38288	20041115
WO 2005048948	A3	20050728		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004291147	A1	20050602	AU 2004-291147	20041115
CA 2545711	AA	20050602	CA 2004-2545711	20041115
US 2005148605	A1	20050707	US 2004-989745	20041115
US 2005165031	A1	20050728	US 2004-989814	20041115
US 2005165024	A1	20050728	US 2004-989824	20041115
US 2005165074	A1	20050728	US 2004-990007	20041115
US 2005171171	A1	20050804	US 2004-989766	20041115
US 2005171172	A1	20050804	US 2004-989823	20041115
US 2005192314	A1	20050901	US 2004-990195	20041115
US 2005197371	A1	20050908	US 2004-990194	20041115
US 2005261315	A1	20051124	US 2004-989623	20041115
US 2005267182	A1	20051201	US 2004-989717	20041115
EP 1684762	A2	20060802	EP 2004-811122	20041115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
PRIORITY APPLN. INFO.:				
			US 2003-520273P	P 20031113
			US 2003-527094P	P 20031203
			US 2003-531082P	P 20031218
			US 2003-531243P	P 20031218
			WO 2004-US38288	W 20041115

OTHER SOURCE(S): MARPAT 143:20052


AB The invention provides methods and compns. for treating conditions mediated by various kinases wherein derivs. of urea compds. are employed. The invention also provides methods of using the compds. and/or compns. in the treatment of a variety of diseases and unwanted conditions in subjects such as cellular proliferative disorders.

IT 852668-55-4  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(urea derivs. as kinase modulators for treatment of cellular proliferative disorders)

PAGE 3-B




PAGE 4-A



RN 852668-55-4 HCAPLUS

CN Urea, N-[4-((6,7-dimethoxy-4-quinazolinyl)amino)phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

t-Bu


L4 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2006 ACS ON STN  
 ACCESSION NUMBER: 2005:429874 HCAPLUS  
 DOCUMENT NUMBER: 144:145392  
 TITLE: The Ipl1/aurora kinase family: Methods of inhibition and functional analysis in mammalian cells  
 AUTHOR(S): Ditchfield, Claire; Keen, Nicholas; Taylor, Stephen S.  
 CORPORATE SOURCE: School of Biological Sciences, University of Manchester, Manchester, UK  
 SOURCE: Methods in Molecular Biology (Totowa, NJ, United States) (2005), 296(Cell Cycle Control), 371-381  
 CODEN: MMBIED; ISSN: 1064-3745  
 PUBLISHER: Humana Press Inc.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB The Ipl1/Aurora family of protein kinases are required for accurate chromosome segregation. Because members of this family are often overexpressed in human tumors, they have recently received much attention, both from the academic community and the pharmaceutical industry. Indeed, two small mol. Aurora kinase inhibitors have recently been described. In this chapter, we describe several methods for investigating the function of the Aurora kinases, focusing on Aurora B. We describe the use of the small-mol. inhibitor ZM447439, RNA interference, and overexpression of a catalytic mutant. All of these methods have proved useful in studying Aurora B as well as validating it as a potential anticancer drug target. However, while all three methods are useful for probing the function of Aurora B, each has inherent advantages and disadvantages. Furthermore, because the mechanism underlying the inhibition is different in each case, caution must be taken when interpreting the data.  
 IT 331771-20-1, ZM447439  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
 (for inhibitor studies of Aurora kinase; methods for inhibition and functional anal. of Ipl1/aurora kinase family in mammalian cells)  
 RN 331771-20-1 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2006 ACS ON STN  
 ACCESSION NUMBER: 2005:395277 HCAPLUS  
 DOCUMENT NUMBER: 142:423807  
 TITLE: Phenyl(quinazolinyl)amines as UL 97-kinase inhibitors for the treatment of human cytomegaloviral and other herpesviral infections  
 INVENTOR(S): Herget, Thomas  
 PATENT ASSIGNEE(S): Akxima Pharmaceuticals A.-G., Germany  
 SOURCE: PCT Int. Appl., 56 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040125	A1	20050506	WO 2004-EP11118	20041005
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG EP 1673346 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK PRIORITY APPLN. INFO.: EP 2003-22647 A 20031006 WO 2004-EP11118 W 20041005 OTHER SOURCE(S): MARPAT 142:423807 GI				



AB The present invention relates to phenyl(quinazolinyl)amine derivs. (shown as 1; variables defined below: e.g. (3,4-dichlorophenyl)(6-methylquinazolin-4-yl)amine) and pharmaceutically acceptable salts thereof and pharmaceutical compns. comprising at least one of these derivs. and/or pharmaceutically salts thereof, as well as the use of these derivs. for the prophylaxis and/or treatment of herpesviral induced infections.


L4 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)  
 including opportunistic infections, esp. for the prophylaxis and/or treatment of infections and diseases induced by human cytomegalovirus (HCMV, a highly specific  $\beta$ -herpesvirus). For 1: R1 = H and Cl-C6-alkyl, aryl, or 4-R18piperazin-1-yl (R18 = 2,4,6-R193phenyl (R19 = H, F, Cl, Br, I, NO2, NH2 or CF3) or furan-2-ylcarbonyl); R2 = H and Cl-C6-alkyl, R3, R4, R5 and R6 = H, Cl-C6-alkyl, Cl-C6-alkoxy, phenoxy, F, Cl, Br, I, OH, CN, NR12R12', N:NR13, NHC(O)R14, NO2, C.tplbond.CR15, C(R20)3, or -CH(R20)2 or O(CH2)omorpholino (o = 0-6), or R4 and R5 together form dioxolan-4,5-diyl or 1H-imidazol-4,5-diyl. R7, R8, R9, R10, and R11 = H, Cl-C6-alkyl, Cl-C6-alkoxy, F, Cl, Br, I, OH, CN, NR12R12', N:NR13, NHC(O)R14, NO2, C.tplbond.CR15, C(R20)3, or CH(R20)2 or O(CH2)omorpholino (o = 0-6) or R8 and R9 together form dioxolan-4,5-diyl or 1H-imidazol-4,5-diyl; addnl. details are given in the claims. Methods of prepn. are not claimed and no example prepn. are included. UL 97-kinase inhibitory and HCMV antiviral activity of some 1 are reported.  
 IT 331770-22-0, Furan-2-carboxylic acid N-[4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]amide 331770-31-1, 2-Cyano-N-[4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]acetamide 457932-98-8, N-[4-(Quinazolin-4-ylamino)phenyl]acetamide 749936-55-3, Furan-2-carboxylic acid N-[3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]amide 851016-98-3, 2-Cyano-N-[3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]acetamide 851017-13-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-14-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-15-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-16-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-17-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-18-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-19-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-20-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-21-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-22-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-23-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-24-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-25-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-26-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-27-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-28-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-29-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-30-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-31-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-32-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-33-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-34-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-35-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-36-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-37-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-38-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-39-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-40-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-41-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-42-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-43-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-44-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-45-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-46-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-47-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-48-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-49-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-50-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-51-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-52-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-53-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-54-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-55-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-56-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-57-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-58-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-59-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-60-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-61-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-62-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-63-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-64-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-65-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-66-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-67-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-68-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-69-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-70-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-71-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-72-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-73-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-74-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-75-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-76-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-77-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-78-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-79-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-80-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-81-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-82-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-83-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-84-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-85-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-86-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-87-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-88-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-89-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-90-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-91-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-92-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-93-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-94-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-95-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-96-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-97-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-98-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851017-99-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-00-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-01-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-02-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-03-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-04-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-05-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-06-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-07-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-08-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-09-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-10-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-11-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-12-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-13-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-14-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-15-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-16-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-17-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-18-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-19-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-20-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-21-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-22-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-23-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-24-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-25-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-26-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-27-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-28-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-29-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-30-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-31-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-32-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-33-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-34-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-35-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-36-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-37-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-38-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-39-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-40-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-41-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-42-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-43-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-44-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-45-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-46-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-47-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-48-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-49-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-50-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-51-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-52-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-53-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-54-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-55-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-56-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-57-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-58-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-59-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-60-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-61-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-62-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-63-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-64-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-65-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-66-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-67-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-68-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-69-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-70-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-71-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-72-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-73-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-74-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-75-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-76-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-77-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-78-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-79-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-80-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-81-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-82-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-83-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-84-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-85-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-86-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-87-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-88-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-89-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-90-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-91-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-92-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-93-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-94-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-95-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-96-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-97-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-98-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851018-99-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-00-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-01-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-02-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-03-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-04-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-05-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-06-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-07-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-08-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-09-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-10-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-11-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-12-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-13-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-14-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-15-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-16-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-17-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-18-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-19-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-20-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-21-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-22-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-23-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-24-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-25-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-26-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-27-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-28-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-29-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-30-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-31-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-32-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-33-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-34-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-35-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-36-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-37-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-38-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-39-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-40-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-41-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-42-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-43-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-44-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-45-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-46-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-47-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-48-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-49-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-50-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-51-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-52-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-53-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-54-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-55-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-56-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-57-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-58-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-59-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-60-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-61-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-62-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-63-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-64-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-65-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-66-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-67-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-68-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-69-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-70-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-71-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-72-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-73-1, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-74-2, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-75-3, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-76-4, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-77-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-78-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-79-7, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-80-8, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-81-9, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-82-0, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide 851019-8




10/ 088,814


L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 457932-98-8 HCAPLUS  
CN Acetamide, N-[4-(4-quinazolylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 749836-55-3 HCAPLUS  
CN 2-Furancarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 851016-98-3 HCAPLUS  
CN Acetamide, 2-cyano-N-[3-[(6,7-dimethoxy-4-quinazolyl)amino]phenyl]-

L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
(9CI) (CA INDEX NAME)



RN 951017-13-5 HCAPLUS  
CN Acetamide, N-[4-[(6-methyl-4-quinazolyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 851017-14-6 HCAPLUS  
CN Acetamide, N-[4-[(8-methyl-4-quinazolyl)amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:220855 HCAPLUS  
DOCUMENT NUMBER: 143:301206  
TITLE: Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts  
AUTHOR(S): Gadea, Bedrick B.; Ruderman, Joan V.  
CORPORATE SOURCE: Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA  
SOURCE: Molecular Biology of the Cell (2005), 16(3), 1305-1318  
CODEN: MBCEEV; ISSN: 1059-1524  
PUBLISHER: American Society for Cell Biology  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB The Aurora family kinases contribute to accurate progression through several mitotic events. ZM447439 ("ZM"), the first Aurora family kinase inhibitor to be developed and characterized, was previously found to interfere with the mitotic spindle integrity checkpoint and chromosome segregation. Here, we have used exts. of Xenopus eggs, which normally proceed through the early embryonic cell cycles in the absence of functional checkpoints, to distinguish between ZM's effects on the basic cell cycle machinery and its effects on checkpoints. ZM clearly had no effect on either the kinetics or amplitude in the oscillations of activity of several key cell cycle regulators. It did, however, have striking effects on chromosome morphol. In the presence of ZM, chromosome condensation began on schedule but then failed to progress properly; instead, the chromosomes underwent premature decondensation during mid-mitosis. ZM strongly interfered with mitotic spindle assembly by inhibiting the formation of microtubules that are nucleated/stabilized by chromatin. By contrast, ZM had little effect on the assembly of microtubules by centrosomes at the spindle poles. Finally, under conditions where the spindle integrity checkpoint was exptl. induced, ZM blocked the establishment, but not the maintenance, of the checkpoint, at a point upstream of the checkpoint protein Mad2. These results show that Aurora kinase activity is required to ensure the maintenance of condensed chromosomes, the generation of chromosome-induced spindle microtubules, and activation of the spindle integrity checkpoint.

IT 331771-20-1, ZM447439  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of spindle integrity checkpoint in Xenopus egg exts.)  
RN 331771-20-1 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-(4-morpholinyl)propoxy]-4-quinazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:29195 HCAPLUS  
 DOCUMENT NUMBER: 142:127561  
 TITLE: Use of aurora kinase inhibitors for reducing the resistance of cancer cells to mitotic spindle assembly inhibitors  
 INVENTOR(S): Anand, Shubha; Venkitaraman, Ashok  
 PATENT ASSIGNEE(S): Cambridge University Technical Services Ltd., UK  
 SOURCE: PCT Int. Appl., 38 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005002571	A1	20050113	WO 2003-GB2862	20030703
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2531142	AA	20050113	CA 2003-2531142	20030703
AU 2003304266	A1	20050121	AU 2003-304266	20030703
US 2006178318	A1	20060810	US 2006-563042	20060313
PRIORITY APPLN. INFO:				WO 2003-GB2862 W 20030703
AB The invention discloses the use of anticancer agents that inhibit mitotic spindle assembly in target cells, including taxanes such as paclitaxel, and in particular to methods and means for predicting and/or reducing the resistance of cancer cells to such agents. Over-expression of aurora kinases, such as Aurora A, mediates resistance to such anti-cancer agents and the resistance of a cancer cell may be reduced by inhibiting aurora kinases and/or predicted by measuring the expression or activity of aurora kinases within the cell.				
IT 331771-20-1 823807-50-7				
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(aurora kinase inhibitors for reducing resistance of cancer cells to mitotic spindle assembly inhibitors)				
RN 331771-20-1 HCAPLUS				
CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				


L4 ANSWER 9 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 823807-50-7 HCAPLUS  
 CN Benzenepropanoic acid,  $\beta$ -(benzoylamino)- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R,BS)-, mixt. with N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 331771-20-1  
 CMF C29 H31 N5 O4




CM 2

CRN 33069-62-4  
 CMF C47 H51 N O14

Absolute stereochemistry. Rotation (-).

L4 ANSWER 9 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1058178 HCAPLUS

DOCUMENT NUMBER: 142:38270

TITLE: A preparation of macrocyclic quinoxaline derivatives, useful as antiproliferative agents

INVENTOR(S): Freyne, Eddy Jean Edgard; Perera, Timothy Pietro Suren; Buijnsters, Peter Jacobus Johannes Antonius; Willems, Marc; Diels, Gaston Stanislas Marcella; Embrechts, Werner Constant Johan; Ten Holte, Peter Janssen Pharmaceutica N.V., Belg.

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 1996 pp.

CODEN: PIXX02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004105765	A1	20041209	WO 2004-EP5621	20040525
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004243487	A1	20041209	AU 2004-243487	20040525
CA 2525214	AA	20041209	CA 2004-2525214	20040525
EP 1633365	A1	20060315	EP 2004-739341	20040525
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004010714	A	20060613	BR 2004-10714	20040525
CN 1794996	A	20060628	CN 2004-80014512	20040525
NO 2005006196	A	20051228	NO 2005-6196	20051227
PRIORITY APPLN. INFO.:				
			WO 2003-EP5723	A 20030527
			WO 2003-EP10266	A 20030915
			WO 2003-EP51061	A 20031218
			WO 2003-EP305723	A 20030527
			WO 2003-EP310266	A 20030915
			WO 2003-EP351061	A 20031218
			WO 2004-EP5621	W 20040525


OTHER SOURCE(S): MARPAT 142:38270

G1

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to a preparation of macrocyclic derivs. of formula I [wherein: Z is O, CH<sub>2</sub>, NH, or S; Y is alk(en/yn)yl, alkyl-C(O)NH, C(O)alkyl, or C(O)NH-alkyl, etc.; X1 and X2 are independently selected

L4 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
from a direct bond. O, O-alkyl, CH<sub>2</sub>, or ON:CH, etc.; R1 is H, CN, halogen, OH, CH<sub>2</sub>, or alkyl, etc.; R2 is H, CN, OH, alkylcarbonyl, or aminocarbonyl, etc.; R3 is H or alkyl; R4 is H, OH, aryl, alkoxy, alkoxy, or alkenyl, etc.; useful as antiproliferative agents. For instance, pyrimidobenzodioxazacyclopentadecine deriv. II [kinase activity: pIC<sub>50</sub> = 7.8, A431 cell (C5): pIC<sub>50</sub> < 6] was prep. via intramol. heterocyclization/etherification of the prep. quinoxaline deriv. III.

IT 807640-31-9P 807640-32-0P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of macrocyclic quinoxaline derivs. useful as antiproliferative agents)

RN 807640-31-9 HCAPLUS

CN Benzamide, N-[3-[[6-(acetyloxy)hexyl]oxy]-4-[[6-(acetyloxy)-7-methoxy-4-quinazolinyl]amino]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 807640-32-0 HCAPLUS

CN Benzamide, 4-fluoro-N-[3-[[6-(hydroxyhexyl)oxy]-4-[[6-(hydroxy-7-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:791974 HCAPLUS

DOCUMENT NUMBER: 141:342890

TITLE: Novel, potent and selective anilinoquinazoline and anilinoquinazolinone inhibitors of p38 MAP kinase

AUTHOR(S): Cumming, John G.; McKenzie, Caroline L.; Bowden, Stuart G.; Campbell, Douglas; Masters, David J.; Breed, Jason; Jewsbury, Philip J.

CORPORATE SOURCE: Mereside, Alderley Park, AstraZeneca, Macclesfield, Cheshire, SK10 4TG, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(21), 5389-5394

CODEN: BWCLEB; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:342890

AB SAR studies led to the identification of 4-(3-benzoylamino-6-methyl-anilino)quinazolines as potent and selective inhibitors of p38 MAP kinase. Further optimization led to the identification of a series of 4-(3-benzoylamino-6-methyl-anilino)pyrimidines as potent inhibitors of the p38 MAP kinase signalling pathway in vitro and in vivo.


IT 153437-75-3P 263400-21-1P 263400-23-3P 263400-28-8P 263400-29-9P 263400-30-2P 721881-54-5P 742684-90-8P 743409-28-1P 748120-10-7P 750558-62-4P 774597-59-0P 774597-60-3P 774597-61-4P 774597-62-5P 774597-63-6P 774597-64-7P 774597-65-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(anilinoquinazoline and anilinoquinazolinone inhibitors of p38 MAP kinase: preparation and SAR)

RN 153437-75-3 HCAPLUS


CN Benzamide, N-[3-[[6,7-dimethoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 263400-21-1 HCAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(dimethylamino)ethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 263400-23-3 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[6-[2-[[bis(1-methylethyl)amino]ethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)]- (9CI) (CA INDEX NAME)




RN 263400-28-8 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)]- (9CI) (CA INDEX NAME)




RN 263400-29-9 HCAPLUS


L4 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 742684-90-8 HCAPLUS  
CN Benzamide, N-[5-[[6,7-dimethoxy-4-quinazolinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 743409-28-1 HCAPLUS  
CN Benzamide, N-[4-chloro-3-[[6,7-dimethoxy-4-quinazolinyl]amino]phenyl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 748120-10-7 HCAPLUS  
CN Benzamide, N-[3-[[6,7-dimethoxy-4-quinazolinyl]amino]-4-methylphenyl]-3-(4-morpholinyl)]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(1-piperidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)]- (9CI) (CA INDEX NAME)




RN 263400-30-2 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)]- (9CI) (CA INDEX NAME)




RN 721881-54-5 HCAPLUS  
CN Benzamide, N-[5-[[6,7-dimethoxy-4-quinazolinyl]amino]-2,4-difluorophenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 750558-62-4 HCAPLUS  
CN Benzamide, N-[3-[[6,7-dimethoxy-4-quinazolinyl]amino]-4-methylphenyl]- (9CI) (CA INDEX NAME)




RN 774597-59-0 HCAPLUS  
CN Benzamide, N-[4-chloro-3-[[6,7-dimethoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 774597-60-3 HCAPLUS  
CN Benzamide, N-[2-chloro-5-[[6,7-dimethoxy-4-quinazolinyl]amino]-4-fluorophenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 774597-61-4 HCAPLUS  
CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 774597-62-5 HCAPLUS  
CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


IT 687995-79-5  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(aminoquinazoline and anilino pyrimidine inhibitors of p38 MAP kinase: preparation and SAR)  
RN 687995-79-5 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[6-(acetyloxy)-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 774597-63-6 HCAPLUS  
CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 774597-64-7 HCAPLUS  
CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 774597-65-8 HCAPLUS  
CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 2004:182368 HCAPLUS  
DOCUMENT NUMBER: 140:229401  
TITLE: Three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands  
INVENTOR(S): Come, Jon H.; Becker, Frank; Kley, Nikolai A.; Reichel, Christoph  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 238 pp., Cont.-in-part of U.S. Ser. No. 91,177.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 6  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004043388	A1	20040304	US 2002-234985	20020903
US 2003165873	A1	20030904	US 2002-91177	20020304
US 2004266854	A1	20041230	US 2004-820453	20040407
PRIORITY APPLN. INFO.:				
			US 2001-272932P	P 20010302
			US 2001-278233P	P 20010323
			US 2001-329437P	P 20011015
			US 2002-91177	A2 20020304
			US 2001-336962P	P 20011203
			WO 2002-US6677	A2 20020304
			US 2002-234985	A2 20020903
			WO 2002-US33052	A2 20021015
			US 2003-460921P	P 20030407
			US 2003-531872P	P 20031223

AB The invention provides compns. and methods for isolating ligand-binding polypeptides for a user-specified ligand, and for isolating small mol. ligands for a user-specified target polypeptide using an improved class of hybrid ligand compds. Preparation of compds., e.g. a methotrexate moiety linked

by a polyethylene glycol moiety to dexamethasone, is described.  
IT 666837-95-2D, conjugates  
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

RN 666837-95-2 HCAPLUS  
CN Benzamide, 3-(dimethylamino)-N-[3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 13 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:339130 HCAPLUS  
DOCUMENT NUMBER: 139:143528  
TITLE: Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores  
AUTHOR(S): Ditchfield, Claire; Johnson, Victoria L.; Tighe, Anthony; Ellston, Rebecca; Haworth, Carolyn; Johnson, Trevor; Mortlock, Andrew; Keen, Nicholas; Taylor, Stephen S.  
CORPORATE SOURCE: School of Biological Sciences, University of Manchester, Manchester, M13 9PT, UK  
SOURCE: Journal of Cell Biology (2003), 161(2), 267-280  
CODEN: JCLBA3; ISSN: 0021-9525  
PUBLISHER: Rockefeller University Press  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB The Aurora/Ipl1 family of protein kinases plays multiple roles in mitosis and cytokinesis. Here, we describe ZM447439, a novel selective Aurora kinase inhibitor. Cells treated with ZM447439 progress through interphase, enter mitosis normally, and assemble bipolar spindles. However, chromosome alignment, segregation, and cytokinesis all fail. Despite the presence of maloriented chromosomes, ZM447439-treated cells exit mitosis with normal kinetics, indicating that the spindle checkpoint is compromised. Indeed, ZM447439 prevents mitotic arrest after exposure to paclitaxel. RNA interference expts. suggest that these phenotypes are due to inhibition of Aurora B, not Aurora A or some other kinase. In the absence of Aurora B function, kinetochore localization of the spindle checkpoint components BubR1, Mad2, and Cenp-E is diminished. Furthermore, inhibition of Aurora B kinase activity prevents the rebinding of BubR1 to metaphase kinetochores after a reduction in centromeric tension. Aurora B kinase activity is also required for phosphorylation of BubR1 on entry into mitosis. Finally, we show that BubR1 is not only required for spindle checkpoint function, but is also required for chromosome alignment. Together, these results suggest that by targeting checkpoint proteins to kinetochores, Aurora B couples chromosome alignment with anaphase onset.  
IT 331771-20-1, ZM 447439  
RI: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores)  
RN 331771-20-1 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:228866 HCAPLUS  
DOCUMENT NUMBER: 134:266317  
TITLE: Preparation of quinazolinones as aurora 2 kinase inhibitors  
INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John; Jung, Frederic Henri; Brewster, Andrew George  
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited  
SOURCE: PCT Int. Appl., 306 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021596	A1	20010329	WO 2000-GB3580	20000918
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2384291	AA	20010329	CA 2000-2384291	20000918
BR 2000014116	A	20020521	BR 2000-14116	20000918
EP 1218354	A1	20020703	EP 2000-960840	20000918
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2003509499	T2	20030311	JP 2001-524975	20000918
EE 200200119	A	20030415	EE 2002-119	20000918
BG 106492	A	20030131	BG 2002-106492	20020307
ZA 2002002234	A	20030619	ZA 2002-2234	20020319
WO 2002001399	A	20020430	WO 2002-1399	20020320
PRIORITY APPLN. INFO.:				
			GB 1999-22154	A 19990921
			GB 1999-22170	A 19990921
			WO 2000-GB3580	W 20000918
OTHER SOURCE(S):			MARPAT 134:266317	
GI				

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Title compds. (I) [wherein X = O, S, SO, SO<sub>2</sub>, NH, or NR<sub>12</sub>; R<sub>12</sub> = H or alkyl; R<sub>1</sub>-R<sub>4</sub> = independently halo, CN, NO<sub>2</sub>, alkylsulfanyl, N(OH)R<sub>13</sub>, or R<sub>15</sub>X<sub>1</sub>; R<sub>13</sub> = H or alkyl; X<sub>1</sub> = a direct bond, O, CH<sub>2</sub>, OC(O), CO, CO<sub>2</sub>, S, SO, SO<sub>2</sub>, or (un)substituted NHCO, CONH, SO<sub>2</sub>NH, NHSO<sub>2</sub>, or NH; R<sub>15</sub> = H or (un)substituted hydrocarbyl, heterocyclyl, or alkoxy; R<sub>5</sub> = NHCO<sub>2</sub>R<sub>9</sub>, NHCOR<sub>9</sub>, NHSO<sub>2</sub>R<sub>9</sub>, COR<sub>9</sub>, CO<sub>2</sub>R<sub>9</sub>, SO<sub>2</sub>R<sub>9</sub>, CONR<sub>10</sub>R<sub>11</sub>, SONR<sub>10</sub>R<sub>11</sub>, or SO<sub>2</sub>NR<sub>10</sub>R<sub>11</sub>; R<sub>9</sub>-R<sub>11</sub> = independently H or (un)substituted hydrocarbyl or heterocyclyl; or R<sub>10</sub> and R<sub>11</sub> together with the N to which they are attached = (un)substituted heterocyclyl; R<sub>6</sub> = H or (un)substituted hydrocarbyl or heterocyclyl; R<sub>7</sub> and R<sub>8</sub> = independently H, halo, alkyl, (di)alkoxy(methyl), alkanoyl, CF<sub>3</sub>, CN, NHY<sub>2</sub>, alkenyl, alkynyl, or (un)substituted Ph, PhCH<sub>2</sub>, or heterocyclyl; or a salt, ester, or amide thereof] were prepared as aurora 2 kinase inhibitors for the treatment of proliferative diseases, such as cancer. For example, a 7-step sequence involving (1) alkylation of morpholine with 1-bromo-3-chloropropane (49%), (2) addition of Et vanillate to yield Et 3-methoxy-4-(3-morpholinopropoxy)benzoate (100%), (3) nitration (86%), (4) reduction to the amine using 10% Pd/C (100%), (5) cycloaddn. with formamide to form the quinazoline (68%), (6) chlorination to give 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (60%), and (7) amination with N-benzoyl-4-aminoaniline (58%) yielded II. The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concentration of 0.0193 μM. In addition, II gave 50% inhibition of MCF-7 cell proliferation at 1.06 μM and reduced BrdU incorporation into cellular DNA by 50% at 0.159-0.209 μM.


IT R<sub>1</sub>: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 331772-11-3 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-14-6 HCAPLUS  
CN Benzamide, N-[4-[[6-hydroxy-7-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-33-9 HCAPLUS  
CN Carbamic acid, [2-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PREP (Preparation); USES (Uses)  
(prepn. of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)  
RN 331770-21-9 HCAPLUS  
CN Benzamide, N-[4-[[6,7-dimethoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-20-1 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




IT 331772-11-3P 331772-14-6P 331772-33-9P  
331772-44-2P 331772-45-3P 331772-47-5P  
331772-51-1P 331772-52-2P 331772-53-3P  
331774-61-9P 331775-47-4P 331775-48-5P  
331775-49-6P 331775-55-4P  
R<sub>1</sub>: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331772-44-2 HCAPLUS  
CN Benzamide, N-[4-[[7-(2-hydroxyethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-45-3 HCAPLUS  
CN Benzamide, N-[4-[[7-(3-chloropropoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 331772-47-5 HCAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, 3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331772-51-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-(2-aminoethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-52-2 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-(3-pyrrolidinyl)oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-53-3 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-(2-pyrrolidinylmethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-61-9 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-(3-(methylamino)propoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331775-47-4 HCAPLUS  
 CN 2-Propenoic acid, 3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331775-48-5 HCAPLUS  
 CN 2-Propenoic acid, 3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331775-49-6 HCAPLUS  
 CN Benzamide, N-[4-[[7-(3-hydroxy-1-propenyl)-6-methoxy-4-

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331775-55-4 HCAPLUS  
 CN Benzamide, N-[4-[[7-amino-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



IT 331770-22-0P 331770-23-1P 331770-24-2P  
 331770-25-3P 331770-26-4P 331770-27-5P  
 331770-28-6P 331770-29-7P 331770-30-0P  
 331770-31-1P 331770-32-2P 331770-33-3P  
 331770-34-4P 331770-35-5P 331770-36-6P  
 331770-37-7P 331770-38-8P 331770-39-9P  
 331770-40-2P 331770-41-3P 331770-42-4P  
 331770-43-5P 331770-44-6P 331770-45-7P  
 331770-46-8P 331770-47-9P 331770-48-0P  
 331770-49-1P 331770-50-4P 331770-51-5P  
 331770-52-6P 331770-53-7P 331770-54-8P  
 331770-55-9P 331770-56-0P 331770-57-1P  
 331770-58-2P 331770-59-3P 331770-60-6P  
 331770-61-7P 331770-62-8P 331770-63-9P  
 331770-64-0P 331770-65-1P 331770-66-2P  
 331770-67-3P 331770-68-4P 331770-69-5P  
 331770-70-8P 331770-71-9P 331770-72-0P  
 331770-73-1P 331770-74-2P 331770-75-3P  
 331770-76-4P 331770-77-5P 331770-78-6P  
 331770-79-7P 331770-80-0P 331770-81-1P




L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

331770-82-2P 331770-83-3P 331770-84-4P  
 331770-85-5P 331770-86-6P 331770-87-7P  
 331770-88-8P 331770-89-9P 331770-90-2P  
 331770-91-3P 331770-92-4P 331770-93-5P  
 331770-94-6P 331770-95-7P 331770-96-8P  
 331770-97-9P 331770-98-0P 331770-99-1P  
 331771-00-7P 331771-01-8P 331771-02-9P  
 331771-03-0P 331771-04-1P 331771-05-2P  
 331771-06-3P 331771-07-4P 331771-08-5P  
 331771-09-6P 331771-10-9P 331771-11-0P  
 331771-12-1P 331771-13-2P 331771-14-3P  
 331771-15-4P 331771-16-5P 331771-17-6P  
 331771-21-2P 331771-22-3P 331771-23-4P  
 331771-24-5P 331771-25-6P 331771-26-7P  
 331771-27-8P 331771-28-9P 331771-29-0P  
 331771-30-3P 331771-31-4P 331771-32-5P  
 331771-33-6P 331771-34-7P 331771-35-8P  
 331771-36-9P 331771-37-0P 331771-38-1P  
 331771-39-2P 331771-40-5P 331771-41-6P  
 331771-42-7P 331771-43-8P 331771-44-9P  
 331771-45-0P 331771-46-1P 331771-47-2P  
 331771-48-3P 331771-49-4P 331771-50-7P  
 331771-51-8P 331771-52-9P 331771-53-0P  
 331771-54-1P 331771-55-2P 331771-56-3P  
 331771-57-4P 331771-58-5P 331771-59-6P  
 331771-60-9P 331771-61-0P 331771-62-1P  
 331771-63-2P 331771-64-3P 331771-65-4P  
 331771-66-5P 331771-67-6P 331771-68-7P  
 331771-69-8P 331771-70-1P 331771-71-2P  
 331771-72-3P 331771-73-4P 331771-74-5P  
 331771-75-6P 331771-76-7P 331771-77-8P  
 331771-78-9P 331771-79-0P 331771-80-3P  
 331771-81-4P 331771-82-5P 331771-83-6P  
 331771-84-7P 331771-85-8P 331771-86-9P  
 331771-87-0P 331771-88-1P 331771-89-2P  
 331771-90-5P 331771-91-6P 331771-92-7P  
 331771-93-8P 331771-94-9P 331771-95-0P  
 331771-96-1P 331771-97-2P 331771-98-3P  
 331771-99-4P 331772-00-0P 331772-01-1P  
 331772-02-2P 331772-03-3P 331772-04-4P  
 331772-05-5P 331772-06-6P 331772-07-7P  
 331772-08-8P 331772-09-9P 331772-10-2P  
 331772-12-4P 331772-15-7P 331772-16-8P  
 331772-17-9P 331772-18-0P 331772-19-1P  
 331772-20-4P 331772-21-5P 331772-22-6P  
 331772-23-7P 331772-24-8P 331772-25-9P  
 331772-26-0P 331772-27-1P 331772-28-2P  
 331772-29-3P 331772-30-6P 331772-31-7P  
 331772-32-8P 331772-34-0P 331772-35-1P  
 331772-36-2P 331772-37-3P 331772-38-4P  
 331772-39-5P 331772-40-8P 331772-41-9P  
 331772-42-0P 331772-43-1P 331772-46-4P  
 331772-48-6P 331772-49-7P 331772-50-0P  
 331772-54-4P 331772-55-5P 331772-56-6P  
 331772-57-7P 331772-58-8P 331772-59-9P  
 331772-60-2P 331772-61-3P 331772-62-4P


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

331772-63-5P 331772-64-6P 331772-65-7P  
 331772-66-8P 331772-67-9P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)  
 RN 331770-22-0 HCAPLUS  
 CN 2-Furancarboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331770-23-1 HCAPLUS  
 CN 2-Propenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-phenyl-, (ZE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331770-24-2 HCAPLUS  
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331770-25-3 HCAPLUS  
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2,4-difluoro- (9CI) (CA INDEX NAME)




RN 331770-26-4 HCAPLUS  
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4,5-dimethoxy-2-nitro- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331770-27-5 HCAPLUS  
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2,4-dinitro- (9CI) (CA INDEX NAME)




PAGE 1-A




RN 331770-28-6 HCAPLUS  
CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 331770-29-7 HCAPLUS  
CN Cyclopentanecarboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331770-30-0 HCAPLUS  
CN 4-Pentenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 331770-31-1 HCAPLUS  
CN Acetamide, 2-cyano-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331770-32-2 HCAPLUS  
CN Octanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331770-33-3 HCAPLUS  
CN Propanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3- (methylthio)- (9CI) (CA INDEX NAME)




RN 331770-34-4 HCAPLUS

CN Propanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-ethoxy- (9CI) (CA INDEX NAME)




RN 331770-35-5 HCAPLUS  
CN 2-Propenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 331770-36-6 HCAPLUS  
CN Pyrazinecarboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-5-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331770-37-7 HCAPLUS  
CN 3-Furancarboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-  
(9CI) (CA INDEX NAME)




RN 331770-38-8 HCAPLUS  
CN Benzamide, 3-cyano-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-  
(9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331770-41-3 HCAPLUS  
CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-  
(methylthio)- (9CI) (CA INDEX NAME)




RN 331770-42-4 HCAPLUS  
CN Benzamide, 3-(acetyloxy)-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-  
(9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331770-39-9 HCAPLUS  
CN Benzamide, 4-(acetyloxy)-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-  
(9CI) (CA INDEX NAME)




RN 331770-40-2 HCAPLUS  
CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-methoxy-2-  
nitro- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331770-43-5 HCAPLUS  
CN 2-Naphthalenecarboxamide, 4-(aminosulfonyl)-N-[4-[(6,7-dimethoxy-4-  
quinazolinyl)amino]phenyl]-1-hydroxy- (9CI) (CA INDEX NAME)




RN 331770-44-6 HCAPLUS  
CN 2-Pyridinecarboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-  
(9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331770-45-7 HCAPLUS  
 CN 2-Quinolinecarboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-  
 (9CI) (CA INDEX NAME)




RN 331770-46-8 HCAPLUS  
 CN 1H-Pyrazole-3-carboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-1,5-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331770-47-9 HCAPLUS  
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-fluoro-5-nitro- (9CI) (CA INDEX NAME)




RN 331770-48-0 HCAPLUS  
 CN 3-Pyridinecarboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331770-49-1 HCAPLUS  
 CN 3-Pyridinecarboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331770-50-4 HCAPLUS  
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331770-51-5 HCAPLUS  
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2,3-difluoro- (9CI) (CA INDEX NAME)




RN 331770-52-6 HCAPLUS  
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2,5-difluoro- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331770-53-7 HCAPLUS  
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2,3-dimethoxy- (9CI) (CA INDEX NAME)



RN 331770-54-8 HCAPLUS  
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-hydroxy-3,5-dimethoxy- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A




PAGE 2-A

RN 331770-57-1 HCAPLUS  
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-methoxy-3-nitro- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331770-55-9 HCAPLUS  
 CN Benzoic acid, 2-chloro-4-[[[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 331770-56-0 HCAPLUS  
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-(methylsulfonyl)-3-nitro- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331770-58-2 HCAPLUS  
 CN 2-Propenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(2-nitrophenyl)-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 331770-59-3 HCAPLUS  
 CN 2-Propenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(3-nitrophenyl)-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331770-60-6 HCAPLUS  
 CN 2-Propenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(4-nitrophenyl)-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 331770-61-7 HCAPLUS  
 CN 2-Propenamide, 3-(4-chlorophenyl)-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331770-62-8 HCAPLUS  
 CN 2-Propenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(2,3,4-trifluorophenyl)-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 331770-63-9 HCAPLUS  
 CN 2-Propenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-[3-(trifluoromethyl)phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331770-64-0 HCAPLUS  
 CN 2-Propenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(4-fluorophenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331770-65-1 HCAPLUS  
 CN 1H-Indole-2-carboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331770-66-2 HCAPLUS  
 CN 1H-Indole-2-carboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-5-fluoro- (9CI) (CA INDEX NAME)




RN 331770-67-3 HCAPLUS  
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 331770-68-4 HCAPLUS  
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3,5-dinitro- (9CI) (CA INDEX NAME)




RN 331770-69-5 HCAPLUS  
CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 331770-70-8 HCAPLUS  
CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

Cl

RN 331770-72-0 HCAPLUS  
CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

Cl

RN 331770-71-9 HCAPLUS  
CN Benzeneacetamide, 4-chloro-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

OMe

RN 331770-73-1 HCAPLUS  
CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 331770-74-2 HCAPLUS  
 CN Benzeneacetamide, N-[(4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl)-3-nitro- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331770-75-3 HCAPLUS  
 CN Propanamide, N-[(4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl)-3-phenoxy- (9CI) (CA INDEX NAME)



RN 331770-76-4 HCAPLUS  
 CN Benzenepropanamide, N-[(4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl)-3,4-dimethoxy- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 331770-77-5 HCAPLUS  
 CN Benzenebutanamide, N-[(4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl)-4-methoxy-γ-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A



RN 331770-78-6 HCAPLUS  
 CN Butanamide, 4-chloro-N-[(4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl)- (9CI) (CA INDEX NAME)






L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331770-79-7 HCAPLUS

CN Butanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-phenoxy- (9CI) (CA INDEX NAME)




RN 331770-80-0 HCAPLUS

CN Benzenebutanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331770-81-1 HCAPLUS

CN Benzenepentanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-8-oxo- (9CI) (CA INDEX NAME)



RN 331770-84-4 HCAPLUS


CN 2-Thiopheneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331770-85-5 HCAPLUS


CN 3-Thiopheneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331770-82-2 HCAPLUS

CN 10-Undecenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331770-83-3 HCAPLUS

CN 2-Pentenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 331770-86-6 HCAPLUS

CN Benzenepropanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-hydroxy-3-nitro- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 2-A




RN 331770-87-7 HCAPLUS  
 CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3,5-difluoro- (9CI) (CA INDEX NAME)



RN 331770-88-8 HCAPLUS  
 CN [1,1'-Biphenyl]-4-acetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




Ph

PAGE 2-A

RN 331770-89-9 HCAPLUS  
 CN 1,3-Benzodioxole-5-acetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331770-90-2 HCAPLUS  
 CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 331770-91-3 HCAPLUS  
 CN Benzeneacetamide, 4-butoxy-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



OBu-n


PAGE 2-A

RN 331770-92-4 HCAPLUS  
 CN Pentanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 331770-93-5 HCAPLUS  
 CN 5-Hexynamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331770-94-6 HCAPLUS  
 CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-phenoxy- (9CI) (CA INDEX NAME)




RN 331770-95-7 HCAPLUS  
 CN 3-Thiophenecarboxamide, 5-bromo-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331770-96-8 HCAPLUS  
 CN 3-Thiophenecarboxamide, 5-chloro-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 331770-97-9 HCAPLUS  
 CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-ethoxy-3-methoxy- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

OEt

RN 331770-98-0 HCAPLUS  
 CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A


O-CH2-Ph

RN 331770-99-1 HCAPLUS  
 CN 2-Thiophenebutanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-00-7 HCAPLUS  
 CN 6-Heptynamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-01-8 HCAPLUS  
 CN Cyclopropanecarboxamide, 1-(4-chlorophenyl)-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-04-1 HCAPLUS  
 CN Cyclohexanecarboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-05-2 HCAPLUS  
 CN Cyclohexanepropionamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-02-9 HCAPLUS  
 CN Cyclopentaneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331771-03-0 HCAPLUS  
 CN Cyclopentanepropanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 331771-06-3 HCAPLUS  
 CN Cyclohexanebutanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-07-4 HCAPLUS  
 CN 2-Propenamido, N-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-methyl-3-phenyl-, (ZE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331771-08-5 HCAPLUS  
 CN Benzamide, N-(2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-09-6 HCAPLUS  
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 331771-10-9 HCAPLUS  
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-3-methylphenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331771-11-0 HCAPLUS  
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 331771-12-1 HCAPLUS  
 CN Benzamide, N-[2-cyano-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-13-2 HCAPLUS

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 331771-14-3 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 331771-15-4 HCAPLUS  
 CN Benzamide, N-[2-cyano-4-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-16-5 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 331771-17-6 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-21-2 HCAPLUS  
CN Carbamic acid, [4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331771-22-3 HCAPLUS  
CN Benzamide, 2-chloro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-5-nitro- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-23-4 HCAPLUS  
CN Acetamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-24-5 HCAPLUS  
CN Octanamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-25-6 HCAPLUS  
CN 2-Furancarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-26-7 HCAPLUS  
CN 3-Furancarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331771-27-8 HCAPLUS  
CN 2-Thiopheneacetamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331771-28-9 HCAPLUS  
CN 1H-Indole-2-carboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




PAGE 1-A




PAGE 2-A


RN 331771-31-4 HCAPLUS  
CN 5-Hexynamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-32-5 HCAPLUS  
CN Benzamide, 2-fluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-5-nitro- (9CI) (CA INDEX NAME)




RN 331771-29-0 HCAPLUS  
CN Benzamide, 2,4-difluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331771-30-3 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-4-(methylsulfonyl)-3-nitro- (9CI) (CA INDEX NAME)




RN 331771-33-6 HCAPLUS  
CN Benzamide, 3-methoxy-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 331771-34-7 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2-(methylthio)- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-35-8 HCAPLUS  
 CN Pyrazinecarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 331771-36-9 HCAPLUS  
 CN 6-Heptynamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-39-2 HCAPLUS  
 CN Benzamide, 4-methoxy-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 331771-40-5 HCAPLUS  
 CN 2-Furancarboxamide, tetrahydro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-37-0 HCAPLUS  
 CN Cyclopentanecarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-38-1 HCAPLUS  
 CN Cyclohexanecarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-41-6 HCAPLUS  
 CN 2-Pyridinecarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331771-42-7 HCAPLUS  
 CN 3-Pyridinecarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)






RN 331771-43-8 HCAPLUS  
CN 2-Propenamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazoliny]amino]phenyl]-3-(4-nitrophenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


PAGE 1-A




PAGE 1-B




RN 331771-44-9 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazoliny]amino]phenyl]-2,4-dinitro- (9CI) (CA INDEX NAME)




RN 331771-45-0 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-46-1 HCAPLUS  
CN 1H-Pyrazole-3-carboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazoliny]amino]phenyl]-1,5-dimethyl- (9CI) (CA INDEX NAME)



RN 331771-47-2 HCAPLUS  
CN Cyclobutanecarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-48-3 HCAPLUS  
CN Benzamide, 2-methoxy-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-49-4 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazoliny]amino]phenyl]-3-nitro- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-50-7 HCAPLUS  
CN Benzanide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazoliny]amino]phenyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 331771-51-8 HCAPLUS  
CN Cyclohexanecarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-54-1 HCAPLUS  
CN Benzanide, 4-fluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazoliny]amino]phenyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 331771-55-2 HCAPLUS  
CN 3-Thiopheneacetamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-52-9 HCAPLUS  
CN 1H-Pyrrole-2-carboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazoliny]amino]phenyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 331771-53-0 HCAPLUS  
CN Benzanide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazoliny]amino]phenyl]-4-methyl-3-nitro- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331771-56-3 HCAPLUS  
CN Benzo[b]thiophene-2-carboxamide, 3-chloro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)





RN 331771-57-4 HCAPLUS  
CN 1H-Indole-2-carboxamide, 5-chloro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-58-5 HCAPLUS  
CN 1-Piperidinepropanamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



RN 331771-62-1 HCAPLUS  
CN Propanamide, 3-(acetyl amino)-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-63-2 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


PAGE 2-A




RN 331771-59-6 HCAPLUS  
CN 1,3-Benzodioxole-5-carboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-60-9 HCAPLUS  
CN 3-Butynamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-61-0 HCAPLUS  
CN Benzamide, 3-cyano-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-64-3 HCAPLUS  
CN Benzamide, 3-chloro-4-fluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-65-4 HCAPLUS  
CN Benzamide, 4-fluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 331771-66-5 HCAPLUS  
CN Benzamide, 4-fluoro-N-[[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-67-6 HCAPLUS  
CN 2-Thiophenecarboxamide, 5-bromo-N-[[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-70-1 HCAPLUS  
CN 2-Furancarboxamide, N-[[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-5-nitro- (9CI) (CA INDEX NAME)




RN 331771-71-2 HCAPLUS  
CN Benzamide, N-[[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2-nitro- (9CI) (CA INDEX NAME)



RN 331771-68-7 HCAPLUS  
CN Benzamide, 4-methoxy-N-[[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-69-8 HCAPLUS  
CN 3-Pyridinecarboxamide, N-[[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 331771-72-3 HCAPLUS  
CN 2-Propenamide, 3-(3-chlorophenyl)-N-[[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-, (2E) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331771-73-4 HCAPLUS  
CN 2-Thiophenecarboxamide, N-[[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2-nitro- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-74-5 HCAPLUS  
 CN Cyclopropanecarboxamide, N-([4-([6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino)phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 331771-75-6 HCAPLUS  
 CN Benzamide, N-([4-([6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino)phenyl]-3-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-76-7 HCAPLUS  
 CN Benzamide, 2-chloro-N-([4-([6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino)phenyl]- (9CI) (CA INDEX NAME)




RN 331771-77-8 HCAPLUS  
 CN Benzamide, 2-fluoro-N-([4-([6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-78-9 HCAPLUS  
 CN Benzamide, 2,5-dichloro-N-([4-([6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino)phenyl]- (9CI) (CA INDEX NAME)




RN 331771-79-0 HCAPLUS  
 CN Benzamide, 3-fluoro-N-([4-([6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-80-3 HCAPLUS  
 CN 3-Pyridinecarboxamide, 6-chloro-N-([4-([6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino)phenyl]- (9CI) (CA INDEX NAME)




RN 331771-81-4 HCAPLUS  
 CN 2-Furancarboxamide, 5-bromo-N-([4-([6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino)phenyl]- (9CI) (CA INDEX NAME)




RN 331771-82-5 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2-methyl-3-nitro- (9CI) (CA INDEX NAME)




RN 331771-83-6 HCAPLUS  
CN Benzamide, 3-chloro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-86-9 HCAPLUS  
CN Cyclopentanecarboxamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-87-0 HCAPLUS  
CN Cyclohexanecarboxamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-84-7 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331771-85-8 HCAPLUS  
CN Benzamide, 2-chloro-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-5-nitro- (9CI) (CA INDEX NAME)




RN 331771-88-1 HCAPLUS  
CN Benzamide, 4-methoxy-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 331771-89-2 HCAPLUS  
CN Octanamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-90-5 HCAPLUS  
CN 2-Furancarboxamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-91-6 HCAPLUS  
CN 3-Furancarboxamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-94-9 HCAPLUS  
CN 2-Furancarboxamide, tetrahydro-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-95-0 HCAPLUS  
CN 2-Pyridinecarboxamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-92-7 HCAPLUS  
CN 2-Thiopheneacetamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-93-8 HCAPLUS  
CN 1H-Indole-2-carboxamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-96-1 HCAPLUS  
CN 3-Pyridinecarboxamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-97-2 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazoliny]amino]phenyl]-2,4-dinitro- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331771-98-3 HCAPLUS  
 CN Benzamide, 2,4-difluoro-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-99-4 HCAPLUS  
 CN 5-Hexynamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 331772-01-1 HCAPLUS  
 CN Propanamide, 3-methoxy-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-02-2 HCAPLUS  
 CN Benzamide, 2-fluoro-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-5-nitro- (9CI) (CA INDEX NAME)




RN 331772-03-3 HCAPLUS  
 CN Benzamide, 3-methoxy-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-2-nitro- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331772-00-0 HCAPLUS  
 CN 3-Thiopheneacetamide, tetrahydro-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A

||  
O

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-04-4 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 331772-05-5 HCAPLUS  
 CN Pyrazinecarboxamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-5-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-06-6 HCAPLUS  
 CN 6-Heptynamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-07-7 HCAPLUS  
 CN Benzamide, 3-(acetyloxy)-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331772-10-2 HCAPLUS  
 CN Benzamide, N-[4-[[6,7-bis(2-methoxyethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-12-4 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-15-7 HCAPLUS

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-08-8 HCAPLUS  
 CN 1H-Pyrazole-3-carboxamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 331772-09-9 HCAPLUS  
 CN Benzamide, N-[4-[[6-(acetyloxy)-7-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CN Benzamide, N-[4-[[7-hydroxy-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-16-8 HCAPLUS  
 CN Benzamide, N-[4-[[7-methoxy-6-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-17-9 HCAPLUS  
 CN Benzamide, N-[4-[[7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-18-0 HCAPLUS  
 CN Benzamide, N-[4-[[6-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-7-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-19-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-methoxy-6-[3-(methylsulfonyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-20-4 HCAPLUS  
 CN Benzamide, N-[4-[[7-methoxy-6-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-21-5 HCAPLUS  
 CN Benzamide, N-[4-[[6-[2-(dimethylamino)ethoxy]-7-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331772-22-6 HCAPLUS  
 CN Benzamide, N-[4-[[7-methoxy-6-(3-pyridinylmethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-23-7 HCAPLUS  
 CN Benzamide, N-[4-[[7-methoxy-6-(2-methoxyethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-24-8 HCAPLUS

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Benzamide, N-[4-[[6-[3-(dimethylamino)propoxy]-7-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-25-9 HCAPLUS  
 CN Benzamide, N-[4-[[7-methoxy-6-(phenylmethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-26-0 HCAPLUS  
 CN Benzamide, N-[4-[[6-(2-hydroxyethoxy)-7-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-27-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-28-2 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-(dimethylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-31-7 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-32-8 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-(methylsulfonyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-29-3 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-30-6 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-(dimethylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-34-0 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-(3-pyridinylmethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-35-1 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-(2-methoxyethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-36-2 HCAPLUS  
CN Benzamide, N-[4-[[7-(acetoxy)-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-37-3 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-[(3,4,5-trifluorophenyl)methoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-38-4 HCAPLUS  
CN Benzamide, N-[4-[[7-(2,3-dihydro-1H-pyrrol-1-yl)propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-39-5 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-[(2Z)-4-(1-pyrrolidinyl)-2-butenyl]oxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-40-8 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-[(2E)-4-(1-pyrrolidinyl)-2-butenyl]oxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331772-41-9 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-[(2Z)-4-(1-piperidinyl)-2-butenyl]oxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331772-42-0 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-[(2E)-4-(4-morpholinyl)-2-butenyl]oxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-43-1 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-[(2E)-4-(4-methyl-1-piperazinyl)-2-butenyl]oxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331772-46-4 HCAPLUS  
CN Benzamide, N-[4-[[6-methoxy-7-[(2S)-oxiranylmethoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331772-48-6 HCAPLUS

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CN Benzamide, N-[4-[[6-methoxy-7-[[1-(1-methylethyl)-3-azetidinyl]oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-49-7 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[(2R)-oxiranylmethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331772-50-0 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-(2,2,2-trifluoroethoxy)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-54-4 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-(4-piperidinylmethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-55-5 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[(1-methyl-2-pyrrolidinyl)methoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331772-56-6 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[(1-methyl-3-pyrrolidinyl)methoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-57-7 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[(1-methyl-3-pyrrolidinyl)oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 331772-58-8 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-[(2-methoxyethyl)methylamino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-59-9 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-(acetylmethylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-60-2 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[[dimethylamino]carbonyl]methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-61-3 HCAPLUS  
 CN Benzamide, N-[4-[[[7-[[[1-(2-hydroxyethyl)-3-pyrrolidinyl]oxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-62-4 HCAPLUS  
 CN Benzamide, N-[4-[[[6-methoxy-7-[[[1-(2-methoxyethyl)-3-pyrrolidinyl]oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-65-7 HCAPLUS  
 CN Benzamide, N-[4-[[[7-[[[1-(cyanomethyl)-4-piperidinyl]oxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-66-8 HCAPLUS  
 CN Benzamide, N-[4-[[[7-[[[1-(cyclopropylmethyl)-2-pyrrolidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-63-5 HCAPLUS  
 CN Benzamide, N-[4-[[[7-[[[1-(cyanomethyl)-3-pyrrolidinyl]oxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-64-6 HCAPLUS  
 CN Benzamide, N-[4-[[[6-methoxy-7-[[[1-(2-methoxyethyl)-4-piperidinyl]oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331772-67-9 HCAPLUS  
 CN Benzamide, N-[4-[[[7-[[[1-(cyclobutylmethyl)-2-pyrrolidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



IT 331772-68-0P 331772-69-1P 331772-70-4P  
 331772-71-5P 331772-72-6P 331772-73-7P  
 331772-74-8P 331772-75-9P 331772-76-0P  
 331772-77-1P 331772-78-2P 331772-79-3P  
 331772-80-6P 331772-81-7P 331772-82-8P  
 331772-83-9P 331772-84-0P 331772-85-1P  
 331772-86-2P 331772-87-3P 331772-88-4P  
 331772-89-5P 331772-90-8P 331772-91-9P  
 331772-92-0P 331772-93-1P 331772-94-2P  
 331772-95-3P 331772-96-4P 331772-97-5P  
 331772-98-6P 331772-99-7P 331773-00-3P  
 331773-01-4P 331773-02-5P 331773-03-6P

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

331773-04-7P 331773-05-8P 331773-06-9P  
 331773-07-0P 331773-08-1P 331773-09-2P  
 331773-10-5P 331773-11-6P 331773-12-7P  
 331773-13-8P 331773-14-9P 331773-15-0P  
 331773-16-1P 331773-17-2P 331773-18-3P  
 331773-19-4P 331773-20-7P 331773-21-8P  
 331773-22-9P 331773-23-0P 331773-24-1P  
 331773-25-2P 331773-26-3P 331773-27-4P  
 331773-28-5P 331773-29-6P 331773-30-9P  
 331773-31-0P 331773-32-1P 331773-33-2P  
 331773-34-3P 331773-35-4P 331773-36-5P  
 331773-37-6P 331773-38-7P 331773-39-8P  
 331773-40-1P 331773-41-2P 331773-42-3P  
 331773-43-4P 331773-44-5P 331773-45-6P  
 331773-46-7P 331773-47-8P 331773-48-9P  
 331773-49-0P 331773-50-3P 331773-51-4P  
 331773-52-5P 331773-53-6P 331773-54-7P  
 331773-55-8P 331773-56-9P 331773-57-0P  
 331773-58-1P 331773-59-2P 331773-60-5P  
 331773-61-6P 331773-62-7P 331773-63-8P  
 331773-64-9P 331773-65-0P 331773-66-1P  
 331773-67-2P 331773-68-3P 331773-69-4P  
 331773-70-7P 331773-71-8P 331773-72-9P  
 331773-73-0P 331773-74-1P 331773-75-2P  
 331773-76-3P 331773-77-4P 331773-78-5P  
 331773-79-6P 331773-80-9P 331773-81-0P  
 331773-82-1P 331773-83-2P 331773-84-3P  
 331773-85-4P 331773-86-5P 331773-87-6P  
 331773-88-7P 331773-89-8P 331773-90-1P  
 331773-91-2P 331773-92-3P 331773-93-4P  
 331773-94-5P 331773-95-6P 331773-96-7P  
 331773-97-8P 331773-98-9P 331773-99-0P  
 331774-00-6P 331774-01-7P 331774-02-8P  
 331774-03-9P 331774-04-0P 331774-05-1P  
 331774-06-2P 331774-07-3P 331774-08-4P  
 331774-09-5P 331774-10-8P 331774-11-9P  
 331774-12-0P 331774-13-1P 331774-15-3P  
 331774-17-5P 331774-18-6P 331774-19-7P  
 331774-20-0P 331774-21-1P 331774-22-2P  
 331774-23-3P 331774-24-4P 331774-25-5P  
 331774-26-6P 331774-27-7P 331774-28-8P  
 331774-29-9P 331774-30-2P 331774-31-3P  
 331774-32-4P 331774-33-5P 331774-34-6P  
 331774-35-7P 331774-36-8P 331774-37-9P  
 331774-38-0P 331774-39-1P 331774-40-4P  
 331774-41-5P 331774-42-6P 331774-43-7P  
 331774-44-8P 331774-45-9P 331774-46-0P  
 331774-47-1P 331774-48-2P 331774-49-3P  
 331774-50-6P 331774-51-7P 331774-52-8P  
 331774-53-9P 331774-54-0P 331774-55-1P  
 331774-56-2P 331774-57-3P 331774-58-4P  
 331774-59-5P 331774-60-8P 331774-62-0P  
 331774-63-1P 331774-64-2P 331774-65-3P  
 331774-66-4P 331774-67-5P 331774-68-6P  
 331774-69-7P 331774-70-0P 331774-71-1P  
 331774-72-2P 331774-73-3P 331774-74-4P


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

331774-75-5P 331774-76-6P 331774-77-7P  
 331774-78-8P 331774-79-9P 331774-80-2P  
 331774-81-3P 331774-82-4P 331774-83-5P  
 331774-84-6P 331774-85-7P 331774-86-8P  
 331774-87-9P 331774-88-0P 331774-89-1P  
 331774-90-4P 331774-91-5P 331774-92-6P  
 331774-93-7P 331774-94-8P 331774-95-9P  
 331774-96-0P 331774-97-1P 331774-98-2P  
 331774-99-3P 331775-00-9P 331775-01-0P  
 331775-02-1P 331775-03-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)

RN 331772-68-0 HCAPLUS


CN Benzamide, N-[4-[[7-[[1-(2-hydroxyethyl)-2-pyrrolidinyl]methoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-69-1 HCAPLUS


CN Benzamide, N-[4-[[7-[[1-(2-ethylthio)ethyl]-2-pyrrolidinyl]methoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-70-4 HCAPLUS

CN Benzamide, N-[4-[[7-[[1-(cyclopropylmethyl)-4-piperidinyl]methoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-71-5 HCAPLUS


CN Benzamide, N-[4-[[7-[[1-(2-hydroxyethyl)-4-piperidinyl]methoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331772-72-6 HCAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[[1-(2-methoxyethyl)-4-piperidinyl]methoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-73-7 HCAPLUS


CN Benzamide, N-[4-[[7-[[1-(cyanomethyl)-4-piperidinyl]methoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-74-8 HCAPLUS

CN Benzamide, N-[4-[[7-[[4,5-dihydro-1H-imidazol-2-yl]methoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-75-9 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-[(2-thienylmethyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-76-0 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[(2-(acetylamino)ethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-79-3 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[[[(1S)-2-amino-1-methyl-2-oxoethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331772-80-6 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-(cyclopropylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-81-7 HCAPLUS

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-77-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[[2-[[bis(1-methylethyl)amino]ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-78-2 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-[(2-(methylthio)ethyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Benzamide, N-[4-[[7-[2-[(cyclopropylmethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-82-8 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-(cyclobutylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-83-9 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-(cyclopentylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-84-0 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[[3-(1H-imidazol-1-yl)propyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-85-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-(cyclohexylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-88-4 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-89-5 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-86-2 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[(4-hydroxycyclohexyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-87-3 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[(cyclohexylmethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-90-8 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[[1,1-bis(hydroxymethyl)propyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-91-9 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[[1,1-bis(hydroxymethyl)-3-methylbutyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-92-0 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[(1-ethyl-2-pyrrolidinyl)methyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-93-1 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331772-94-2 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-[(tetrahydro-2-furanyl)methyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-95-3 HCAPLUS  
 CN 4-Piperidinecarboxamide, 1-[2-[[4-[(4-benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331772-96-4 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-[[2-(4-morpholinyl)ethyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-97-5 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-[[3-(4-morpholinyl)propyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-98-6 HCAPLUS

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-[[2-(1-piperidinyl)ethyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-99-7 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-[[2-(1-pyrrolidinyl)ethyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-00-3 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[(2-hydroxy-1,1-dimethylpentyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-01-4 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[(2-hydroxy-1,1-dimethylethyl)amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-02-5 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[(3-hydroxy-1,1-dimethylpropyl)amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-05-8 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[(1-(hydroxymethyl)propyl)amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-06-9 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[(2,3-dihydroxypropyl)amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-03-6 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-[(1-methylethyl)amino]ethoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-04-7 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[(2-hydroxy-1-methylethyl)amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331773-07-0 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[(2-(dimethylamino)ethyl)amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-08-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[(2-(diethylamino)ethyl)amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331773-09-2 HCAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[(2-methoxyethyl)amino]ethoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331773-10-5 HCAPLUS

CN Benzamide, N-[4-[[7-[2-[(2-hydroxyethyl)amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-11-6 HCAPLUS

CN Benzamide, N-[4-[[7-[2-[(2-hydroxyethyl)amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

EtS-CH2-CH2-NH-CH2-CH2-O-




RN 331773-14-9 HCAPLUS

CN Benzamide, N-[4-[[7-[2-[(3-ethoxypropyl)amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-15-0 HCAPLUS

CN Benzamide, N-[4-[[7-[2-[(3-butoxypropyl)amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-16-1 HCAPLUS

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331773-12-7 HCAPLUS

CN Benzamide, N-[4-[[7-[2-[(2-mercaptoethyl)amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-13-8 HCAPLUS

CN Benzamide, N-[4-[[7-[2-[(2-ethylthio)ethyl]amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Benzamide, N-[4-[[7-[2-[(3-hydroxypropyl)amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331773-17-2 HCAPLUS


CN Benzamide, N-[4-[[7-[2-[(5-hydroxypentyl)amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-18-3 HCAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[(2-methoxy-1-methylethyl)amino]ethoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-19-4 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[(4-hydroxybutyl)amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-20-7 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-[(5-methyl-1H-pyrazol-3-yl)amino]ethoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-21-8 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-[[3-(4-methyl-1-piperazinyl)propyl]amino]ethoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-22-9 HCAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[[2-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyloxy]ethyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331773-23-0 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[[2-(dibutylamino)ethyl]amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-24-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[[2-(diethylamino)ethyl]amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-25-2 HCAPLUS

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Benzamide, N-[4-[[7-[2-[[2-(2-hydroxycyclohexyl)methyl]amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-26-3 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-[[2-(2-thienyl)ethyl]amino]ethoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-27-4 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[[1-(hydroxymethyl)pentyl]amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-28-5 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[[4-hydroxy-1-(methylthio)butyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-29-6 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-[(1-methyl-2-pyrrolidinyl)ethyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-32-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[(3-hydroxy-2,2-dimethylpropyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-33-2 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-[(3-thienylmethyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-30-9 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-[(5-methyl-2-furyl)methyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-31-0 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-[(tetrahydro-1,1-dioxido-3-thienyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331773-34-3 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-[(4-thiomorpholinyl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-35-4 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[(2-hydroxyethyl)[2-(4-morpholinyl)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331773-36-5 HCAPLUS

CN Benzamide, N-[4-[[7-[2-[[bis(2-hydroxyethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-37-6 HCAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-(1-piperidinyl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-38-7 HCAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[(4-pyridinylmethyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331773-41-2 HCAPLUS


CN Benzamide, N-[4-[[6-methoxy-7-[2-[methyl(methylsulfonyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331773-42-3 HCAPLUS


CN Benzamide, N-[4-[[7-[2-(diethylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-39-8 HCAPLUS

CN Benzamide, N-[4-[[7-[2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-40-1 HCAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-(methylamino)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331773-43-4 HCAPLUS


CN Benzamide, N-[4-[[7-[2-[(hexahydro-1H-azepin-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-44-5 HCAPLUS

CN Benzamide, N-[4-[[7-[2-[(2-hydroxyethyl)methylamino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-45-6 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-(2,5-dihydro-1H-pyrrol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-46-7 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[(2-(dimethylamino)ethyl)methylamino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-47-8 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-(4-methyl-1-piperazinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-48-9 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-(4-cyclopropyl-1-piperazinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-49-0 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331773-50-3 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-(4-hydroxy-1-piperidinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 331773-51-4 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[(2-(4-morpholinyl)ethyl)-1-piperazinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-52-5 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[(4-(3-hydroxypropyl)-1-piperazinyl]ethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-53-6 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[ethyl(2-hydroxyethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-54-7 HCAPLUS  
 CN Benzanide, N-[4-[[7-[2-(3-hydroxy-1-pyrrolidinyl)ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-55-8 HCAPLUS  
 CN Benzanide, N-[4-[[7-[2-(2-cyanoethyl)methylamino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-56-9 HCAPLUS  
 CN Benzanide, N-[4-[[7-[2-(1,4'-bipiperidin-1'-ylethoxy)-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-57-0 HCAPLUS  
 CN Benzanide, N-[4-[[7-[2-(3,5-dimethyl-4-morpholinyl)ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-58-1 HCAPLUS  
 CN Benzanide, N-[4-[[7-[2-(4-acetyl-1-piperazinyl)ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-59-2 HCAPLUS  
 CN Benzanide, N-[4-[[7-[2-(methyl-2-propenylamino)ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-60-5 HCAPLUS  
 CN Benzanide, N-[4-[[7-[2-(2-methyl-1-pyrrolidinyl)ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-61-6 HCAPLUS  
 CN Benzanide, N-[4-[[7-[2-[ethyl(1-methylethyl)amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-62-7 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-(2-cyanoethyl)ethylamino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-63-8 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-[methyl(2-methylpropyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-66-1 HCAPLUS  
 CN 2-Thiazolidinecarboxylic acid, 3-[2-[[4-[(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 331773-67-2 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-(2-hydroxyethyl)-1-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-64-9 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-(4-ethyl-1-piperazinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-65-0 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-(4-fluorophenyl)-1-piperazinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 331773-68-3 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-[methyl(3-pyridinylmethyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-69-4 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-[methyl(2-pyridinylmethyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-70-7 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-(2,5-dimethyl-1-pyrrolidinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-71-8 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-(3,6-dihydro-1(2H)-pyridinyl)ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-72-9 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[2-(4-methyl-1-piperidinyl)ethoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-73-0 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[4-(2-hydroxyethyl)-1-piperazinyl]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-74-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-[2-(2-hydroxyethyl)-1-piperidinyl]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331773-75-2 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-(2-ethyl-4,5-dihydro-1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-76-3 HCAPLUS  
 CN Benzamide, N-[4-[[7-[2-(4,5-dihydro-1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 331773-77-4 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[[2-(acetamido)ethyl]amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-78-5 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[[2-(2-amino-1-methyl-2-oxoethyl)amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331773-79-6 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-(cyclopropylamino)propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-80-9 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(cyclopropylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-81-0 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(cyclobutylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-82-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(cyclopentylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-83-2 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[[3-(1H-imidazol-1-yl)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-84-3 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(cyclohexylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-85-4 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(4-hydroxycyclohexyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-86-5 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(cyclohexylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-87-6 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-88-7 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[[[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-89-8 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[[[1,1-bis(hydroxymethyl)propyl]amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331773-92-3 HCAPLUS  
 CN 4-Piperidinecarboxamide, 1-[3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazoliny]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 331773-93-4 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-[[2-(4-morpholinyl)ethyl]amino]propoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-94-5 HCAPLUS

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331773-90-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[[[1S]-1-(hydroxymethyl)-3-methylbutyl]amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 331773-91-2 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-[[tetrahydro-2-furanyl]methyl]amino]propoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Benzamide, N-[4-[[7-[3-[[2-hydroxy-1,1-dimethylethyl]amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-95-6 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[[3-hydroxy-1,1-dimethylpropyl]amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-96-7 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-[[1-methylethyl]amino]propoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-97-8 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(2-hydroxy-1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-98-9 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(1-hydroxymethyl)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331773-99-0 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(2,3-dihydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-00-6 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-[(2-methoxyethyl)amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331774-01-7 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(2-(2-hydroxyethoxy)ethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-02-8 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(2-mercaptoethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-03-9 HCAPLUS

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Benzamide, N-[4-[[7-[3-[(2-ethylthio)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-04-0 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[[3-(diethylamino)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-05-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(3-ethoxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331774-06-2 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(3-hydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-07-3 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(5-hydroxypentyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331774-10-8 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(2-hydroxycyclohexyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-11-9 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(1-hydroxyhexyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331774-08-4 HCAPLUS  
 CN 2-Pyrrolidinecarboxamide, 1-[3-[[4-[(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-09-5 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-[(5-methyl-1H-pyrazol-3-yl)amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331774-12-0 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-[(5-methyl-2-furanyl)methyl]amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-13-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(3-hydroxy-2,2-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331774-15-3 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-[(3-thienylmethyl)amino]propoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-17-5 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331774-20-0 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-(1-piperidiny)propoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-21-1 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-22-2 HCAPLUS

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331774-18-6 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-[(2-thienylmethyl)amino]propoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-19-7 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(1-piperidiny)propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Benzamide, N-[4-[[7-[3-[(diethylamino)propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-23-3 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[[bis(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-24-4 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-[[methyl(1-methyl-3-pyrrolidiny)amino]propoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331774-25-5 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-[methyl(2-methylamino)-2-oxoethyl]amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-26-6 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-(2-oxo-1-piperazinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331774-29-9 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-(3,5-dimethyl-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-30-2 HCAPLUS  
 CN Pentitol, 1,5-anhydro-2-[[3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]methylamino]-2,4-dideoxy-3-C-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331774-27-7 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-[(tetrahydro-4-hydroxy-3-furanyl)amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-28-8 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-methyl-1-piperidinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331774-31-3 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-(2-cyclopenten-1-ylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-32-4 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(2S,4R)-4-hydroxy-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331774-33-5 HCAPLUS  
 CN threo-Pentitol, 1,5-anhydro-3-[[3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]methylamino]-2,3-dideoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 331774-34-6 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(cyclobutylmethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331774-35-7 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-(3-hydroxy-1-azetidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-36-8 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(2-cyanoethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331774-37-9 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-[methyl[2-(4-morpholinyl)ethyl]amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-38-0 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-[4-(2-methoxyethyl)-1-piperazinyl]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331774-39-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(3,5-dimethyl-4-morpholinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-40-4 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-thiomorpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331774-41-5 HCAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(2-methyl-1-piperidinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-42-6 HCAPLUS


CN Benzamide, N-[4-[[7-[3-(2,6-dimethyl-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-43-7 HCAPLUS


CN Benzamide, N-[4-[[7-[3-[2-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331774-46-0 HCAPLUS

CN Benzamide, N-[4-[[7-[3-[bis(2-methoxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-47-1 HCAPLUS

CN Benzamide, N-[4-[[7-[3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331774-44-8 HCAPLUS

CN Benzamide, N-[4-[[7-[3-(3-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-45-9 HCAPLUS

CN Benzamide, N-[4-[[7-[3-(2,5-dihydro-1H-pyrrol-1-yl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331774-48-2 HCAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[4-(1-methylethyl)-1-piperazinyl]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-49-3 HCAPLUS


CN Benzamide, N-[4-[[6-methoxy-7-[3-[methyl(2-tetrahydro-2-furanyl)methyl]amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-50-6 HCAPLUS


CN Benzamide, N-[4-[[7-[3-(4-acetyl-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331774-51-7 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(3R)-3-hydroxy-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-52-8 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(1-methyl-4-piperidinyl]amino]propoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331774-53-9 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(1-methyl-4-piperidinyl]amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-54-0 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(1-methyl-4-piperidinyl]amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331774-55-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(1-methyl-4-piperidinyl]amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-56-2 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(1-methyl-4-piperidinyl]amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 331774-57-3 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(1-methyl-4-piperidinyl]amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-58-4 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(1-methyl-4-piperidinyl]amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-59-5 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(1-methyl-4-piperidinyl]amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331774-60-8 HCAPLUS  
 CN Benzamide, N-[4-[[7-[3-[(2R,5R)-2,5-dimethyl-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 331774-62-0 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-3-[(2-(dimethylamino)ethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331774-65-3 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-66-4 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-3-[(2-(ethylthio)ethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-67-5 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-3-[(3-(diethylamino)propyl]amino]-2-

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331774-63-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-3-[(2-(diethylamino)ethyl]amino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-64-2 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(2-(2-hydroxyethoxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331774-68-6 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-3-[(3-ethoxypropyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-69-7 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(3-hydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331774-70-0 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(5-hydroxypentyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-71-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(4-hydroxybutyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331774-74-4 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[[2-(2-thienyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-75-5 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[[1-(hydroxymethyl)pentyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-76-6 HCAPLUS

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331774-72-2 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(5-methyl-1H-pyrazol-3-yl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-73-3 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(1-hydroxycyclohexyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331774-77-7 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[[5-methyl-2-furanyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-78-8 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(3-hydroxy-2,2-dimethylpropyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331774-79-9 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(3-thienylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-80-2 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(2,3-dihydroxypropyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331774-83-5 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(1H-imidazol-1-yl)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-84-6 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-3-(cyclohexylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-85-7 HCAPLUS

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331774-81-3 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-3-(cyclobutylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-82-4 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-3-(cyclopentylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CN Benzamide, N-[4-[[7-[(2R)-3-[(cyclohexylmethyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331774-86-8 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-87-9 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 088,814

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331774-88-0 HCAPLUS  
CN Benzamide, N-[4-[[7-[(2R)-3-[[1,1-bis(hydroxymethyl)propyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-89-1 HCAPLUS  
CN Benzamide, N-[4-[[7-[(2R)-3-[[1-ethyl-2-pyrrolidinylmethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331774-90-4 HCAPLUS  
CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[[[tetrahydro-2-furanyl]methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-91-5 HCAPLUS  
CN 4-Piperidinecarboxamide, 1-[(2R)-3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331774-92-6 HCAPLUS  
CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[[2-(4-morpholinyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-93-7 HCAPLUS  
CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331774-94-8 HCAPLUS  
CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(3-hydroxy-1,1-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331774-95-9 HCAPLUS  
CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-96-0 HCAPLUS




L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(2-hydroxy-1-methylethyl)amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331774-97-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-3-(cyclopropylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-98-2 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(2-thienylmethyl)amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331775-01-0 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(2-(1-piperidinyl)ethyl)amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-02-1 HCAPLUS  
 CN 2-Pyrrolidinecarboxamide, 1-[(2S)-3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyloxy]-2-hydroxypropyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-03-2 HCAPLUS

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331774-99-3 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-3-[(2-(acetylthio)ethyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-00-9 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(2-(methylthio)ethyl)amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[[(1S)-1-(hydroxymethyl)-3-methylbutyl]amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 331775-04-3P 331775-05-4P 331775-06-5P  
 331775-07-6P 331775-08-7P 331775-09-8P  
 331775-10-1P 331775-11-2P 331775-12-3P  
 331775-13-4P 331775-14-5P 331775-15-6P  
 331775-16-7P 331775-17-8P 331775-18-9P  
 331775-19-0P 331775-20-3P 331775-21-4P  
 331775-22-5P 331775-23-6P 331775-24-7P  
 331775-25-8P 331775-26-9P 331775-27-0P  
 331775-28-1P 331775-29-2P 331775-30-5P  
 331775-31-6P 331775-32-7P 331775-33-8P  
 331775-34-9P 331775-35-0P 331775-36-1P  
 331775-37-2P 331775-38-3P 331775-39-4P  
 331775-40-7P 331775-41-8P 331775-42-9P  
 331775-43-0P 331775-44-1P 331775-45-2P  
 331775-46-3P 331775-47-9P 331775-48-0P  
 331775-49-1P 331775-50-2P 331775-51-3P  
 331775-52-4P 331775-53-5P 331775-54-6P  
 331775-55-7P 331775-56-8P 331775-57-9P  
 331810-24-3P 331825-58-2P 331825-60-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)

RN 331775-04-3 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[[(1R)-1-(hydroxymethyl)propyl]amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331775-05-4 HCAPLUS  
 CN 2-Pyrrolidinecarboxamide, 1-[(2R)-3-[[4-[(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]-2-hydroxypropyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-06-5 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[[1S]-1-(hydroxymethyl)-3-methylbutyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331775-07-6 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[[1R]-1-(hydroxymethyl)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-08-7 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-3-[[2-(dimethylamino)ethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331775-09-8 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[2-(2-hydroxyethoxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-10-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-11-2 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-3-[[2-(ethylthio)ethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331775-12-3 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-3-[[3-(diethylamino)propyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-13-4 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-3-[(3-ethoxypropyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331775-14-5 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(3-hydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-15-6 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(5-hydroxypentyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331775-18-9 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(1-hydroxycyclohexyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-19-0 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(2-thienyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-20-3 HCAPLUS

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331775-16-7 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(4-hydroxybutyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-17-8 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(5-methyl-1H-pyrazol-3-yl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[1-(hydroxymethyl)pentyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331775-21-4 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-22-5 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[5-methyl-2-furanyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331775-23-6 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(3-hydroxy-2,2-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-24-7 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(3-thienylmethyl)amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331775-27-0 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-3-(cyclohexylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-28-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-3-[(cyclohexylmethyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-29-2 HCAPLUS

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331775-25-8 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-3-(cyclobutylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-26-9 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2R)-3-(cyclopentylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331775-30-5 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-3-[[1,1-bis(hydroxymethyl)propyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-31-6 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(2S)-3-[[1-ethyl-2-pyrrolidinyl)methyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331775-32-7 HCAPLUS  
CN Benzamide, N-[4-[[[7-(2S)-2-hydroxy-3-[[[tetrahydro-2-furanyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-  
(9CI) [CA INDEX NAME]


**Absolute stereochemistry.**



RN 331775-33-8 HCAPLUS  
CN 4-Piperidinecarboxamide, 1-[[2S]-3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


**Absolute stereochemistry.**

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331775-36-1 HCAPLUS  
CN Benzamide, N-(4-[[7-(2S)-2-hydroxy-3-[(3-hydroxy-1,1-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-37-2 HCAPLUS  
CN Benzamide, N-[4-[7-[ (2S) -2-hydroxy-3-[(1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**




RN 331775-38-3 HCAPLUS

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331775-34-9 HCAPLUS  
CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[2-(4-morpholinyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**




RN 331775-35-0 HCAPLUS  
CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


ANSWER 14 OF 19 NCAP03 COPYRIGHT 2000 ACS ON STN (continued)  
CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(2-hydroxy-1-  
methyl ethyl) amino] propoxy]-6-methoxy-4-quinazolinyl] amino] phenyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 331775-39-4 HCAPLUS  
CN Benzamide, N-[4-[[7-[(2S)-3-(cyclopropylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


**Absolute stereochemistry.**



RN 331775-40-7 HCAPLUS  
CN Benamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(2-thienylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331775-41-8 HCAPLUS

CN Benzamide, N-[4-[[7-[(2S)-3-[[2-(acetamino)ethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-42-9 HCAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[2-(methylthio)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331775-43-0 HCAPLUS

CN Benzamide, N-[4-[[7-[(2R)-3-[bis(2-hydroxyethyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-44-1 HCAPLUS


CN Phosphoric acid, 2-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331775-45-2 HCAPLUS


CN Phosphoric acid, 2-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 331775-46-3 HCAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[(2-phosphonoxy)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331775-50-9 HCAPLUS


CN Benzamide, N-[4-[[6-methoxy-7-[(1E)-3-oxo-3-(1-piperidinyl)-1-propenyl]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331775-51-0 HCAPLUS


CN Benzamide, N-[4-[[7-(3-hydroxypropyl)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




10/ 088,814

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RN 331775-52-1 HCAPLUS  
 CN Benzamide, N-[4-[[7-[(1E)-3-[4-[2-(dimethylamino)ethyl]-1-piperazinyl]-3-oxo-1-propenyl]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331775-53-2 HCAPLUS  
 CN Benzamide, N-[4-[[7-(3-hydroxy-3-methyl-1-butynyl)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331775-54-3 HCAPLUS  
 CN Benzamide, N-[4-[[7-(3-hydroxy-1-propynyl)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331775-56-5 HCAPLUS  
 CN 4-Pyridinecarboxamide, N-[4-[[4-(benzoylamino)phenyl]amino]-7-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 331775-57-6 HCAPLUS  
 CN 1-Piperidinepropanamide, N-[4-[[4-(benzoylamino)phenyl]amino]-7-quinazolinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331775-58-7 HCAPLUS  
 CN Benzamide, N-[4-[[7-[[[acetyloxy]acetyl]amino]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331810-24-3 HCAPLUS  
 CN 2-Pyrrolidinecarboxamide, 1-[3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331825-58-2 HCAPLUS  
 CN Benzamide, N-[4-[[7-[[[2S]-2-hydroxy-3-[(4-hydroxycyclohexyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331825-60-6 HCAPLUS  
 CN Benzamide, N-[4-[[7-[[[2R]-2-hydroxy-3-[(4-hydroxycyclohexyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 330999-74-1, 4-(4-(N-Boc-amino)anilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline dihydrochloride 331776-52-4,


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 4-((4-(N-Benzoylamino)anilino)-6-methoxy-7-(2,2,2-trifluoroethoxy)quinazoline  
 331776-55-7 331776-56-8 331776-57-9,  
 4-((4-(N-Benzoylamino)anilino)-6-methoxy-7-hydroxyquinazoline  
 trifluoroacetate 331776-58-0, 4-((4-(N-Benzoylamino)anilino)-6-  
 methoxy-7-benzoyloxyquinazoline trifluoroacetate 331776-59-1  
 331776-60-4 331776-61-5, 4-((4-(N-Benzoylamino)anilino)-  
 6-methoxy-7-(4-piperidinoyl)quinazoline 331776-65-9,  
 4-((4-(N-Benzoylamino)anilino)-6-methoxy-7-(2-bromoethoxy)quinazoline  
 331776-68-2, (R)-4-((4-(N-Benzoylamino)anilino)-6-methoxy-7-  
 (glycidyl)quinazoline 331776-69-3 331776-71-7  
 331776-79-5, 4-((4-(N-Benzoylamino)anilino)-7-nitroquinazoline  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reactant; prepn. of 4-substituted quinazoline aurora 2 kinase  
 inhibitors for treatment of cancer and other proliferative diseases)  
 RN 330999-74-1 HCAPLUS  
 CN Carbamic acid, [4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-  
 quinazolinyl]amino]phenyl]-, 1,1-dimethylethyl ester, dihydrochloride  
 (9CI) (CA INDEX NAME)




● 2 HCl

RN 331776-52-4 HCAPLUS  
 CN Carbamic acid, [4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-  
 quinazolinyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX  
 NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331776-55-7 HCAPLUS  
 CN Benzamide, N-[4-[[6-(acetyloxy)-7-methoxy-4-quinazolinyl]amino]phenyl]-,  
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 331776-56-8 HCAPLUS  
 CN Benzamide, N-[4-[[6-(hydroxy-7-methoxy-4-quinazolinyl)amino]phenyl]-,  
 monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● HCl

RN 331776-57-9 HCAPLUS  
 CN Benzamide, N-[4-[[7-hydroxy-6-methoxy-4-quinazolinyl]amino]phenyl]-,  
 mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 331772-15-7  
 CMF C22 H18 N4 O3



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 331776-58-0 HCAPLUS  
 CN Benzamide, N-[4-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]phenyl]-,  
 mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 331772-11-3  
 CMF C29 H24 N4 O3



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2




RN 331776-59-1 HCAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[[4-(benzoylamino)phenyl]amino]-6-  
 methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA  
 INDEX NAME)



L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331776-60-4 HCAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[[[4-[(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331776-61-5 HCAPLUS  
 CN Benzamide, N-[4-[[[6-methoxy-7-(4-piperidinyl)oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 331776-69-3 HCAPLUS  
 CN Phosphonic acid, [2-[[[4-[(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)




RN 331776-71-7 HCAPLUS  
 CN Methanesulfonic acid, trifluoro-, 4-[[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl] ester (9CI) (CA INDEX NAME)




RN 331776-79-5 HCAPLUS  
 CN Benzamide, N-[4-[(7-nitro-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331776-65-9 HCAPLUS  
 CN Benzamide, N-[4-[(7-(2-bromoethoxy)-6-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331776-68-2 HCAPLUS  
 CN Benzamide, N-[4-[[[6-methoxy-7-[(2R)-oxiranylmethyl]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 15 OF 19 HCAPLUS COPYRIGHT 2006 ACS ON STN  
 ACCESSION NUMBER: 2001:228864 HCAPLUS  
 DOCUMENT NUMBER: 134:252355  
 TITLE: Preparation of quinazolines as aurora 2 kinase inhibitors  
 INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John  
 PATENT ASSIGNEE(S): AstraZeneca AB, Sued.; AstraZeneca UK Limited  
 SOURCE: PCT Int. Appl., 101 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021594	A1	20010329	WO 2000-GB3556	20000918
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2384282	AA	20010329	CA 2000-2384282	20000918
BR 2000014133	A	20020611	BR 2000-14133	20000918
TR 200200749	T2	20020621	TR 2002-749	20000918
EP 1218356	A1	20020703	EP 2000-962677	20000918
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, NO, MK, CY, AL			
JP 2003509497	T2	20030311	JP 2001-524973	20000918
EE 200200149	A	20030415	EE 2002-149	20000918
AU 763242	B2	20030717	AU 2000-74325	20000918
ZA 2002001833	A	20030605	ZA 2002-1833	20020305
BG 106491	A	20021229	BG 2002-106491	20020307
NO 2002001401	A	20020521	NO 2002-1401	20020320
US 7081461	B1	20060725	US 2002-88854	20020321

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 134:252355  
 G1


L4 ANSWER 15 OF 19 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



● 2 HCl

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 19 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



AB Title compds. (I) [wherein X = O, S, SO, SO<sub>2</sub>, NH, or NR<sub>8</sub>; R<sub>8</sub> = H or alkyl; R<sub>1</sub> = (un)substituted 3-quinolinyl or Ph; R<sub>1</sub>-R<sub>4</sub> = independently halo, CN, NO<sub>2</sub>, alkylsulfanyl, N(OH)R<sub>12</sub>, or R<sub>14</sub>X<sub>1</sub>; R<sub>12</sub> = H or alkyl; X<sub>1</sub> = a direct bond, O, CH<sub>2</sub>, OC(O), CO, S, SO, SO<sub>2</sub>, or (un)substituted NHCO, CONH, SO<sub>2</sub>NH, NHSO<sub>2</sub>, or NH; R<sub>14</sub> = H or (un)substituted hydrocarbyl, heterocyclyl, or alkony; or a salt, ester, or amide thereof] were prepared as aurora 2 kinase inhibitors for the treatment of proliferative diseases, such as cancer. For example, 4-phenoxyaniline+HCl and 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline were refluxed in i-PrOH to yield II (86%). The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concentration of 0.069 μM. In addition, II gave 50% inhibition of MCF-7 cell proliferation at 2.89 μM and reduced BrdU incorporation into cellular DNA by 50% at 3.68 μM.

IT 330999-74-1P, 4-[(N-Boc-amino)anilino]-6-methoxy-7-(3-morpholinopropoxy)quinazoline dihydrochloride

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)

RN 330999-74-1 HCAPLUS

CN Carbamic acid, [4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-, 1,1-dimethylethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS ON STN


ACCESSION NUMBER: 2000:241203 HCAPLUS  
 DOCUMENT NUMBER: 132:265207  
 TITLE: Preparation of 4-anilinoquinazolines and 4-anilinoquinolines as inhibitors of cytokine mediated disease  
 INVENTOR(S): Cumming, John Graham  
 PATENT ASSIGNEE(S): Zeneca Limited, UK  
 SOURCE: PCT Int. Appl., 101 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000020402	A1	20000413	WO 1999-GB3220	19990927
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2341374	AA	20000413	CA 1999-2341374	19990927
AU 9961064	A1	20000426	AU 1999-61064	19990927
AU 761552	B2	20030605		
BR 9914162	A	20010626	BR 1999-14162	19990927
EP 1117653	A1	20010725	EP 1999-947686	19990927
EP 1117653	B1	20030205		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002526538	T2	20020820	JP 2000-574519	19990927
AT 232205	E	20030215	AT 1999-947686	19990927
NZ 510210	A	20030630	NZ 1999-510210	19990927
PT 1117653	T	20030630	PT 1999-947686	19990927
ES 2191462	T3	20030901	ES 1999-947686	19990927
ZA 2001002187	A	20020618	ZA 2001-2187	20010315
US 6593333	B1	20030715	US 2001-787883	20010323
NO 2001001631	A	20010521	NO 2001-1631	20010330
NO 318892	B1	20050518		
HK 1037367	A1	20030822	HK 2001-108138	20011119
US 2003216417	A1	20031120	US 2003-441084	20030520
US 6716847	B2	20040406		


PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 132:265207  
 G1

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II


AB The title compds. [I: G = N, CH; R1 = OH, halo, CF3, etc.; R2, R3 = H, halo, alkyl, etc.; R4 = H, OH, alkyl, etc.; R5 = H, halo, CF3; m = 1-3; q = 0-4] and their pharmaceutically acceptable salts or in vivo cleavable esters, useful in the treatment of diseases or medical conditions mediated by cytokines, were prepared and formulated. E.g., a multi-step synthesis of II which showed IC50 of 0.2  $\mu$ M against p38 $\alpha$  kinase and IC50 of 5.2  $\mu$ M against TNF $\alpha$  production, was given.

IT 263400-17-5P 263400-18-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of 4-anilinoquinazolines and 4-anilinoquinolines as inhibitors of cytokine mediated disease)

RN 263400-17-5 HCAPLUS  
 CN 4-Pyridinecarboxamide, N-[3-[(6-(acetyloxy)-7-methoxy-4-quinazolinyl)amino]-4-methylphenyl]-2-(4-morpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

263400-30-2P 263400-31-3P 263400-32-4P  
 263400-33-5P 263400-34-6P 263400-35-7P  
 263400-36-8P 263400-37-9P 263400-38-0P  
 263400-39-1P 263400-40-4P 263400-41-5P  
 263400-42-6P 263400-43-7P 263400-44-8P  
 263400-45-9P 263400-46-0P 263400-48-2P  
 263400-50-6P 263400-51-7P 263400-52-8P  
 263400-53-9P 263400-94-8P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of 4-anilinoquinazolines and 4-anilinoquinolines as inhibitors of cytokine mediated disease)  
 RN 263399-67-3 HCAPLUS  
 CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-68-4 HCAPLUS  
 CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3,4-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 2 HCl


RN 263400-18-6 HCAPLUS  
 CN 4-Pyridinecarboxamide, N-[3-[(6-hydroxy-7-methoxy-4-quinazolinyl)amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



IT 263399-67-3P 263399-68-4P 263399-70-8P  
 263399-71-9P 263399-72-0P 263399-74-2P  
 263399-75-3P 263399-76-4P 263399-77-5P  
 263399-78-6P 263399-79-7P 263399-80-0P  
 263399-81-1P 263399-82-2P 263399-83-3P  
 263399-84-4P 263399-85-5P 263399-86-6P  
 263399-87-7P 263399-88-8P 263399-89-9P  
 263399-90-2P 263399-91-3P 263399-92-4P  
 263399-93-5P 263399-94-6P 263399-95-7P  
 263399-96-8P 263399-97-9P 263399-98-0P  
 263399-99-1P 263400-00-6P 263400-01-7P  
 263400-03-9P 263400-04-0P 263400-05-1P  
 263400-06-2P 263400-07-3P 263400-08-4P  
 263400-09-5P 263400-10-8P 263400-11-9P  
 263400-12-0P 263400-13-1P 263400-19-7P  
 263400-20-0P 263400-21-1P 263400-22-2P  
 263400-23-3P 263400-25-5P 263400-26-6P  
 263400-27-7P 263400-28-8P 263400-29-9P


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 263399-70-8 HCAPLUS  
 CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-71-9 HCAPLUS  
 CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-72-0 HCAPLUS  
 CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl


RN 263399-74-2 HCAPLUS  
 CN Benzamide, 4-cyano-N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-75-3 HCAPLUS  
 CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-3-(dimethylamino)-, dihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 2 HCl


RN 263399-76-4 HCAPLUS  
 CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-cyano-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-77-5 HCAPLUS  
 CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(dimethylamino)-, dihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 2 HCl


RN 263399-78-6 HCAPLUS  
 CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-79-7 HCAPLUS  
 CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-fluorophenyl]-3-(dimethylamino)-, dihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● 2 HCl

RN 263399-80-0 HCAPLUS  
 CN Acetamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-81-1 HCAPLUS  
 CN Propanamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-82-2 HCAPLUS  
 CN Acetamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-83-3 HCAPLUS  
 CN Propanamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-84-4 HCAPLUS  
 CN Acetamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-85-5 HCAPLUS  
 CN Acetamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-86-6 HCAPLUS  
 CN Acetamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-87-7 HCAPLUS  
 CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-fluorophenyl]-4-cyano-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-88-8 HCAPLUS  
 CN 2-Furancarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-89-9 HCAPLUS  
 CN 3-Pyridinecarboxamide, 6-chloro-N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl


RN 263399-90-2 HCAPLUS  
 CN 5-Isoxazolecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-91-3 HCAPLUS  
 CN Benzamide, 3-(dimethylamino)-N-[4-methyl-3-[(6,7,8-trimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 263399-92-4 HCAPLUS  
 CN Carbamic acid, [5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 263399-93-5 HCAPLUS  
 CN Benzamide, 4-cyano-N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● HCl

RN 263399-94-6 HCAPLUS  
 CN Benzamide, N-[2-fluoro-5-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 263399-95-7 HCAPLUS  
 CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(dimethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl


RN 263399-96-8 HCAPLUS  
 CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-97-9 HCAPLUS  
 CN Benzamide, N-[4-chloro-3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl


RN 263399-98-0 HCAPLUS  
 CN Benzamide, 4-cyano-N-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-99-1 HCAPLUS  
 CN Benzamide, N-[4-chloro-3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-cyano-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl


RN 263400-00-6 HCAPLUS  
 CN Benzamide, N-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-3-(dimethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263400-01-7 HCAPLUS  
 CN Benzamide, N-[4-chloro-3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(dimethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl


RN 263400-03-9 HCAPLUS  
 CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2,4-difluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263400-04-0 HCAPLUS  
 CN Benzamide, N-[4-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-3-(dimethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl


RN 263400-05-1 HCAPLUS  
 CN Benzamide, 3-(dimethylamino)-N-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263400-06-2 HCAPLUS  
 CN Acetamide, N-[4-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl


RN 263400-07-3 HCAPLUS  
 CN Acetamide, N-[2-fluoro-5-[[6-methoxy-7-[3-(3-pyridinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 263400-08-4 HCAPLUS  
 CN Acetamide, N-[2-fluoro-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 2 HCl


RN 263400-09-5 HCAPLUS  
 CN Acetamide, N-[2-fluoro-5-[[6-methoxy-7-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl]amino]phenyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 263400-10-8 HCAPLUS  
 CN Acetamide, N-[2-fluoro-5-[[6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]phenyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 2 HCl


RN 263400-11-9 HCAPLUS  
 CN Benzamide, N-[3-[[6,7-dimethoxy-4-quinazolinyl]amino]-4-methylphenyl]-3-(4-morpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 263400-12-0 HCAPLUS  
 CN 4-Pyridinecarboxamide, N-[3-[[6,7-dimethoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 263400-13-1 HCAPLUS  
 CN Benzamide, N-[2-fluoro-5-[[6,7,8-trimethoxy-4-quinazolinyl]amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 263400-19-7 HCAPLUS  
 CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(diethylamino)-2-oxoethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 263400-20-0 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[6-(2-(dimethylamino)-2-oxoethoxy)-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-21-1 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[6-(2-(dimethylamino)ethoxy)-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-22-2 HCAPLUS


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 263400-26-6 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[6-(3-(diethylamino)propoxy)-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-27-7 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[6-(2-(dimethylamino)-2-methylpropoxy)-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-28-8 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
CN 4-Pyridinecarboxamide, N-[3-[[6-(2-(diethylamino)ethoxy)-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-23-3 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[6-(2-[bis(1-methylethyl)amino]ethoxy)-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-25-5 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[6-(3-(dimethylamino)propoxy)-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 263400-29-9 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(1-piperidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-30-2 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-31-3 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 263400-32-4 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-33-5 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-34-6 HCAPLUS


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 263400-37-9 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[3-(1-methyl-5-oxo-2-piperidinyl)methoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-38-0 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(2-oxo-1-imidazolidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-39-1 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-[(1-methyl-3-piperidinyl)methoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-35-7 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[1-(methyl-2-piperidinyl)methoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-36-8 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[1-(methyl-3-piperidinyl)methoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 263400-40-4 HCAPLUS  
CN Benzamide, 4-cyano-N-[3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-41-5 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-42-6 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[[7-fluoro-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)


10/ 088,814

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● 2 HCl

RN 263400-43-7 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[(6-methoxy-7-[(3-methylsulfonyl)propoxy]-4-quinazoliny]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-44-8 HCAPLUS  
CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazoliny]amino]-4-methylphenyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl


RN 263400-45-9 HCAPLUS  
CN 2-Thiophenecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazoliny]amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263400-46-0 HCAPLUS  
CN Cyclopropanecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazoliny]amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl


RN 263400-48-2 HCAPLUS  
CN Acetamide, N-[3-[(6,7-dimethoxy-4-quinazoliny]amino]-4-methylphenyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263400-50-6 HCAPLUS  
CN Carbamic acid, [5-[(6,7-dimethoxy-4-quinazoliny]amino]-2-fluorophenyl]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 263400-51-7 HCAPLUS  
CN Benzamide, 4-cyano-N-[3-[(6-methoxy-7-[(3-methylsulfonyl)propoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 263400-52-8 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazoliny]amino]phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-53-9 HCAPLUS  
CN 4-Pyridinecarboxamide, N-[3-[(6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-4-quinazoliny]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 263400-94-8 HCAPLUS  
 CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-  
 (9CI) (CA INDEX NAME)




IT 263400-86-8P 263400-87-9P  
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of 4-anilinoquinazolines and 4-anilinoquinolines as  
 inhibitors  
 of cytokine mediated disease)  
 RN 263400-86-8 HCAPLUS  
 CN 4-Pyridinecarboxamide, N-[3-[(7-hydroxy-6-methoxy-4-quinazolinyl)amino]-4-  
 methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 263400-87-9 HCAPLUS  
 CN 4-Pyridinecarboxamide, N-[3-[(6-methoxy-7-(phenylmethoxy)-4-  
 quinazolinyl)amino]-4-methylphenyl]-2-(4-morpholinyl)-, dihydrochloride  
 (9CI) (CA INDEX NAME)



● 2 HC1

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 1998:105843 HCAPLUS  
 DOCUMENT NUMBER: 128:136497  
 TITLE: Aryl and heteroaryl quinazoline compounds which  
 inhibit EGF and/or PDGF receptor tyrosine kinase  
 INVENTOR(S): Myers, Michael R.; Spada, Alfred P.; Maguire, Martin  
 P.; Persons, Paul E.  
 PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA  
 SOURCE: U.S., 19 pp., Cont.-in-part of U.S. 5,480,883.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5710158	A	19980120	US 1994-229886	19940419
US 5480883	A	19960102	US 1993-166199	19931210
WO 9515758	A1	19950615	WO 1994-US14180	19941208
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9513050	A1	19950627	AU 1995-13050	19941208
EP 871448	A1	19981021	EP 1995-904308	19941208
EP 871448	B1	20050302		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
EP 1488792	A2	20041222	EP 2004-19772	19941208
EP 1488792	A3	20050105		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
AT 289814	E	20050315	AT 1995-904308	19941208
PT 871448	T	20050531	PT 1995-904308	19941208
ES 2236701	T3	20050716	ES 1995-904308	19941208
US 5656643	A	19970812	US 1995-385258	19950208
US 6645969	B1	20031111	US 1995-521852	19950518
US 5714493	A	19980203	US 1996-652444	19960604
US 37650	E	20020409	US 2000-496399	20000202
US 2004014774	A1	20040122	US 2003-617342	20030710
PRIORITY APPLN. INFO.:				
			B2 19910510	
			US 1992-988515	B2 19921210
			US 1993-166199	A2 19931210
			WO 1992-US3736	A2 19920506
			US 1993-146072	A3 19931108
			US 1994-229886	A 19940419
			EP 1995-904308	A3 19941208
			WO 1994-US14180	W 19941208
			US 1995-521852	A3 19950518
			US 1996-652444	A5 19960604

OTHER SOURCE(S): MARPAT 128:136497  
 AB This invention relates to the modulation and/or inhibition of cell  
 signaling, cell proliferation, cell inflammatory response, the control of  
 abnormal cell growth and cell reproduction. More specifically, this  
 invention  
 relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline  
 compds. in inhibiting cell proliferation, including compds. which are  
 useful protein tyrosine kinase (PTK) inhibitors. The method of treating  
 cell proliferation using said quinazoline compds. and their use in  
 pharmaceutical compns. is described. A number of compds. were tested for

L4 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

inhibition of PDGF receptor cell-free antophosphorylation procedure.  
 IT 202475-66-9  
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES  
 (Uses)  
 (aryl and heteroaryl quinazoline compds. which inhibit EGF and/or PDGF  
 receptor tyrosine kinase)  
 RN 202475-66-9 HCAPLUS  
 CN Acetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA  
 INDEX NAME)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:462220 HCAPLUS

DOCUMENT NUMBER: 125:114665

TITLE: Preparation of quinoline and quinazoline protein

tyrosine kinase inhibitors

INVENTOR(S): Hudson, Alan Thomas; Vile, Sadie; Barraclough, Paul; Franzmann, Karl Witold; McKeown, Stephen Carl; Page, Martin John

PATENT ASSIGNEE(S): Wellcome Foundation Limited, UK

SOURCE: PCT Int. Appl., 139 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9609294	A1	19960328	WO 1995-GB2202	19950918
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9534824	A1	19960409	AU 1995-34824	19950918
ZA 9507853	A	19970318	ZA 1995-7853	19950918
EP 782570	A1	19970709	EP 1995-931351	19950918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10505600	T2	19980602	JP 1995-509740	19950918
PRIORITY APPLN. INFO.:				
			GB 1994-18852	A 19940919
			GB 1995-7788	A 19950413
			GB 1995-10757	A 19950526
			WO 1995-GB2202	W 19950918


OTHER SOURCE(S): MARPAT 125:114665

GI



L4 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



● HCl


L4 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB The title compds. [I: X = N, CH; Y = W(CH<sub>2</sub>), (CH<sub>2</sub>)<sub>2</sub>W, W = O, S(O)m, (un)substituted NH; R<sub>1</sub> = NH<sub>2</sub>, H, halogen, OH, NO<sub>2</sub>, CO<sub>2</sub>H, CF<sub>3</sub>, CF<sub>3</sub>O, ureido, etc.; R<sub>4</sub> = H, OH, halogen, alkyl, alkoxy, alkylthio, CN, NO<sub>2</sub>, CF<sub>3</sub>, etc.; n = 1-3; R<sub>5</sub> = H, halogen, CF<sub>3</sub>, alkyl, alkoxy; R<sub>6</sub> = substituted hydrocarbyl, etc.], which are protein tyrosine kinase inhibitors, are prepared. Thus, 4-chloroquinoline was reacted with 4-methoxyaniline in the presence of HCl, producing 4-(4-phenoxyanilino)quinoline hydrochloride, m.p. 216-218°, which demonstrated a IC<sub>50</sub> against p56lck protein tyrosine kinase of 5 μM.

IT 179247-41-7P 179247-42-8P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of quinoline and quinazoline protein tyrosine kinase inhibitors)

RN 179247-41-7 HCAPLUS

CN Benzamide, N-[4-(4-quinazolinylamino)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 179247-42-8 HCAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1994:217715 HCAPLUS

DOCUMENT NUMBER: 120:217715

TITLE: Quinazoline tyrosine kinase-inhibiting anticancer

agents

INVENTOR(S): Barker, Andrew J.

PATENT ASSIGNEE(S): Zeneca Ltd., UK

SOURCE: Can. Pat. Appl., 99 pp.

CODEN: CPXXEB

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2086968	AA	19930721	CA 1993-2086968	19930108
CA 2086968	C	19980623		
ZA 9300015	A	19930720	ZA 1993-15	19930104
AU 9331010	A1	19930722	AU 1993-31010	19930104
AU 661533	B2	19950727		
HU 63153	A2	19930728	HU 1993-94	19930115
EP 566226	A1	19931020	EP 1993-300270	19930115
EP 566226	B1	19951108		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 130000	E	19951115	AT 1993-300270	19930115
ES 2078798	T3	19951216	ES 1993-300270	19930115
CZ 282038	B6	19970416	CZ 1993-43	19930118
NO 9300178	A	19930721	NO 1993-178	19930119
NO 301541	B1	19971110		
RU 2127263	C1	19990310	RU 1993-4423	19930119
SK 281551	B6	20010510	SK 1993-16	19930119
FI 111631	B1	20030829	FI 1993-208	19930119
KR 229294	B1	19991101	KR 1993-645	19930120
IL 104479	A1	19991222	IL 1993-104479	19930121
JP 06073025	A2	19940315	JP 1993-26577	19930216
JP 2994165	B2	19991227		
US 5457105	A	19951010	US 1994-284293	19940802
US 5616582	A	19970401	US 1995-490666	19950615
PRIORITY APPLN. INFO.:				
			GB 1992-1095	A 19920120
			GB 1992-13572	A 19920626
			GB 1992-23735	A 19921112
			US 1993-5280	B1 19930119
			US 1994-284293	A1 19940802

OTHER SOURCE(S): MARPAT 120:217715

GI

AB The title compds. I [R<sub>1</sub> = HO, (un)substituted amino, carboxy, carbamoyl,

L4 ANSWER 19 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 urido, etc.: R2 = H, HO, halogen, CF3, NH2, NO2, CN, (un)substituted C1-4  
 alkyl, etc.: m = 1-3; n = 1, 2], useful as tyrosine kinase-inhibiting  
 anticancer agents (no data), are prepd. and l-contg. formulations  
 presented. Thus, 4-chloro-6,7-dimethoxyquinazoline was condensed with  
 3-MeC6H4NH2, producing 6,7-dimethoxy-4-(3'-methylaniilino)quinazoline  
 hydrochloride, m.p. 248-249°.  
 IT 153437-74-2P 153437-75-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of, as tyrosine kinase-inhibiting anticancer agent)  
 RN 153437-74-2 HCAPLUS  
 CN Acetamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA  
 INDEX NAME)



RN 153437-75-3 HCAPLUS  
 CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA  
 INDEX NAME)

